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                                 INTRODUCTION 
Colorectal Carcinoma is one of the emerging cancers,which is the 
leading cause of cancer related deaths in developed countries. It stands 
as third most common malignancy in men and second most common in 
women worldwide.
( 1)
 The American Cancer Society estimates around 
97,220 new cases of colon cancer and 43,030 new cases of rectal cancer 
in United states for 2018. 
In India, CRC occupies the fifth most common position following 
breast, cervix/uteri, oralcavity and lung cancers 
(3)
.The incidence rates 
of colon cancer in India vary from 0.7 to 3.7 per 1Lakh population 
among men and 0.4 to 3/ 1 lakh  among women. For rectal carcinoma it 
varies from 1.6 to 5.5 per 1Lakh among men and  0 to 2.8 per 1 Lakh 
among women.
(10) 
A statistical review of  population based cancer regist ries from12 
major cities of India have demonstrated that incidence of colorectal 
carcinoma is significantly lower in India compared to west. 
(4)
 
CRC is the carcinoma of old age occurring mostly after fifth 
decade of life.
(2) 
However,its incidence is increasing in younger age 
especially in developing counts, mainly due to the life style and food 
habit changes. 
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Its development involves a multistep process signified by genetic 
alterations that have been considered to occur in a stepwise manner. 
Two major genetic pathways have been put forth: 
(5)
 
 Chromosomal Instability (ChieflyAPC/ß-CATENIN) 
 Microsatellite Instability pathway(MSI) 
Additional mutations accumulate in wide range of genes and 
proteins like KRAS, NRAS, BRAF,PIK3CA,MAPK,PTEN,TP53 and 
SMAD triggering the downstream signaling cascades in evolution of 
colorectal carcinogenesis. DNA mismatch repair deficiency leading to 
microsatellite instability and CpG island hypermethylation are other 
proposed pathways leading to tumorigenesis. 
Among the various genetic mutations,KRAS oncogene mutation 
has a pivotal role  associated with proliferation and decreased 
apoptosis.Importance of KRAS mutational status assay has been 
highlighted in recent years due to its theranostic significance.  
Identifying KRAS mutational status in each patient is significant 
in order to determine the best therapy.Patients with colorectal carcinoma 
can fall into either of the categories:  
 KRAS Wild type  (WT)- which means KRAS gene in its 
natural,non-mutant form.They can receive monoclonal ant ibodies 
against EGFR 
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 KRAS Mutational type –associated with no response to targeted 
therapies 
The development of molecular biology and genetic techniques  
has contributed to a better understanding of carcinogenesis predicting its 
evolution.Attempt of early diagnosis, selection of appropriate targeted 
therapies and efficient follow up can play a novel role in reducing the 
disease related mortalities and morbidities. 
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AIMS AND OBJECTIVES 
 To evaluate the expression of K-RAS mutation in colorectal 
carcinoma. 
 To study its correlation with respect to age,histological findings 
and staging of carcinoma. 
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REVIEW OF LITERATURE 
HISTORICAL ASPECTS 
Over 100 years ago, Dr.Alfred Warthin first suspected the 
hereditary colorectal disorder  in the family of an affected woman who 
subsequently died of endometrial carcinoma.He began to research on her 
family ailments and in 1913, published his first report documenting a 
pattern of endometrial cancer and gastrointestinal cancers,particularly of 
gastric and colon cancers (7).In 1960‟s the development of colonoscope 
revolutionized in colorectal surgical field.In 1971,Lynch and Krush did 
elaborate studies on her family and showed it to be what was latter 
known as Lynch syndrome. Cutaneous manifestations such as sebaceous 
adenomas and carcinomas coming under Muir-Torre syndrome were also 
associated with this disorder. Knudson‟s two hit hypothesis suggested 
the basis of understanding of how tumor suppressor genes could explain 
the onset of familial cancers at younger age group as well as the variable 
penetrance. Although there is increased susceptibility,second mutations 
are required for producing a tumor.  
Mutations in adenomatous polypsis coli(APC) gene are 
responsible for syndrome originally recognized in 1930‟s as autosomal 
dominant familial severe polyposis ,at present being known as Familial 
adenomatous polyposis(FAP) (8). Identification of hereditary and 
familial mutations allowed presymptomatic genetic testing in family 
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members leading to earlier detection of related cancers and possibly 
preventing them at premalignant stages increasing their survival. 
Technological advances now throw insight into new genetic discoveries 
leading to the understanding of CRC tumorigenesis. 
EMBRYOLOGY OF COLON AND RECTUM 
The embryonic gastrointestinal tract starts developing during 
fourth week of gestation.The gut  is derived from endoderm and consists 
of Foregut,Midgut and Hindgut.  Both MIDGUT and HINDGUT 
contributes to development of colon and rectum. Part of midgut forms a 
loop that is divisible into prearterial and postarterial segments.  
Ascending colon develops from postarterial segment of midgut 
loop.As a result of rotation ,caecum(developed from caecal bud from 
postarterial segment of midgut loop) and ascending colon comes to lie 
on right side.Thus midgut forms ascending colon and proximal 
transverse colon,both of which receives superior mesentric artery 
supply. 
The hindgut develops into distal transverse colon,descending 
colon,rectum and proximal anus.All of them receive their blood supply 
from the inferior mesenteric artery.  
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Fig-1: Rotation of Gut Fig-2:Embryological Development 
Of Gut 
ANATOMY: (6) 
The Large intestine is the terminal part of alimentary canal 
extending from distal end of ileum to anus ,with approximate distance of 
1.5 meters. The general characteristics of large intestine includes -
TAENIAE COLI, APPENDICES EPIPLOICA and HAUSTRA OF COLON 
Large intestine is subdivided into four main regions consisting of 
caecum, colon,rectum and anus. 
Caecum(Proximal right colon)-Intraperitoneal pouch which is 6x9 cm 
Appendix-A vermiform diverticulum in various poitions ,usually located 
in lower cecum. 
Ascending Colon-20 to 25cm long ,passes upwards lying 
retroperitoneally.When it meets right lobe of liver,it turns 90 degrees 
horizontally as HEPATIC FLEXURE of colon. 
Transverse colon-It extends from hepatic flexure to spleen where it 
turns another 90 degrees inferiorly as SPLENIC FLEXURE.  
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Descending Colon-10 to 15 cm lying retroperitoneally. 
Sigmoid colon-40cm long extending from left iliac fossa to level of S3 
vertebra, surrounded by sigmoid mesocolon 
Rectum-is the next 12cm structure lying retroperitoneally  
BLOOD SUPPLY  
The Marginal artery of Drummond is a clinically important 
collateral supply to colon. 
Midgut derived structures - Middle colic,Right colic and 
Ileocolic arteries of superior mesenteric artery. Appendicular branch of 
ileocolic artery supplies appendix.  
Hindgut derived structures-Left colic artery,sigmoidal ateries 
and superior rectal artery. Similar to arterial supply,corresponding veins 
drain the parts of colon and rectum.  
NERVE SUPPLY  
Midgut derived structures receive their sympathetic,  
parasympathetic and sensory supply via nerves from superior mesenteri c 
plexus.  Hindgut derived structures from inferior mesenteric plexus via 
splanchnic nerves. 
LYMPHATICS 
    Lymphatics of colon drains into superior and inferior 
mesenteric nodes, and finally on to the cistern chyli emptying into 
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thoracic duct.Upper half of rectum reach pararectal nodes and lower half 
reach internal iliac nodes.  
HISTOLOGY: 
(90)
    
There are four distinct functional layers:  
1) MUCOSA of colon is lined by simple columnar epithelium,containing 
crypts of Lieberkuhn with numerous goblet cells. 
2) SUBMUCOSA –This layer of loose collagenous connective tissue 
blood vessels, submucosal plexus of nerves and lymphatics. 
3) MUSCULARIS PROPRIA- The muscle wall proper consists of 
smooth muscles arranged in 2 layers: Outer longitudinal layer and 
Inner circular layer. 
4) SEROSA-Outer layer of loose supporting tissue  lined by single layer 
of flattened to cuboidal mesothelial cells with fibro elastic tissue. 
 
Fig-3: Layers Of Gastrointestinal  Tract-Colon&Rectum 
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Fig-4 : Histological Layers Of Colon 
EPIDEMIOLOGY: 
TheAmerican cancer society has estimated number of colorectal 
cancer cases in United stated for 2018 .The number of new cases of 
colorectal cancer that can be detected are 97,220 and 43,030 new cases 
of rectal cancer.There is an acceleration in decline from about 2% per 
year prior in mid- 2000‟s to 3% per year from 2004-2013, which reflects 
detection through screening and removal of precancerous polyps. 
GLOBOCAN 2018 estimates over 1.8 million new colorectal cancer 
cases and 881,000 deaths to occur and accounting for 6.1%of 
carcinomas of all sites.
(9)
 
This disease can be considered as a marker of socioeconomic 
development. In countries undergoing major development transition 
,there is an increasing trend in incidence rates uniformly with increasing 
Human Development Index(HDI).This rise in incidence rates ,by various 
period-cohort study, points to the influence of dietary habits,obesity,  
lifestyle factors.At the same time,decline in mortality in more developed 
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countries are attributed to adoption of best practices in cancer treatment 
leading to improvements in survival.  
In India,the incidence rates of colorectal carcinoma are low 
compared that of western world.Incidence rates of colon cancer varies 
from 0.7-3.7 per 1lakh among men; 0.4-3 per 1lakh among women 
.Rectal carcinoma incidence varies from 1.6-5.5/1lakh among men and 
0-2.8/1lakh among women
(10)
. 
 
Fig-5: Seer’s Trend of CRC  
 
Fig 6:Seer 9 Delay-Adjusted Rates 
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RISK FACTORS  
The etiology of colorectal carcinoma is multifactorial in 
nature.Notably- dietary factors, genetic factors and environmental 
factors . 
 
Fig-7:  List Of Riskfactors For Colorectal Carcinoma 
NON MODIFIABLE RISK FACTORS: 
(11)
 
1) Age: As age advances,risk of developing colorectal carcinoma 
also increases. SMost people are diagnosed with age more than 50 
years.Patients with age older than 70 years mostly present with 
early-stage disease ,whereas patients of younger age diagnosed in 
their earlier age less than 40 years present with much 
aggressiveness for a given stage of presentation.
(12)
 
2) Gender: The Role of gender in association with development of 
colorectal carcinoma remains unclear.Although men are more 
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likely to develop rectal carcinoma,there were no differences in 
post operative mortality between the sexes.  
3) Races: There are racial differences in colonic cancer survival as 
demonstrated by several literatures.African ,American have higher 
incidence and lower survival rates than Caucasians and other 
racial groups.  
4) Family History: Patients with significant family history of 
colonic cancer or polyps in first degree relatives are at increased 
risk of developing it.  
5) Familial Adenomatous Polyposis: Germline mutation of APC 
gene referred as “gatekeeper” of colonic neoplastic 
progression,located on chromosome 5q21 is associated with 
FAP.They have relatively higher risk of developing CRC.Other 
syndromes with APC mutations such as Gardner‟s syndrome and 
Turcot syndrome also been associated with risk of colonic cancer. 
By Wilmink A BM  study,it is seen that FAP accounts for 1% of 
CRC. 
(14)
 
Other inherited syndromes like Cowden‟s, Peutz-Jegher‟s and 
Muirr-torre syndromes also have association with colorectal carcinomas.  
1) Hereditary Nonpolyposis Colorectal Cancer (Lynch syndrome): 
It is an inherited autosomal dominant trait caused by several DNA 
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mismatch (MMR)genes.Amsterdam criteria for colorectal cancer 
includes: 
(13) 
a. Atleast three family members with cancers are associated with 
HNPCC –One must be a first degree relative.  
b. Atleast two successive generations must be affected  
c. Atleast one of the relatives must have been diagnosed before 
age of 50. 
2) Inflammatory Bowel Disease: Both Ulcerative colitis and crohn‟s 
disease are prone to develop colorectal cancer.
(19)
 There is an 
estimated risk between 4 to 20 folds of developing CRC.Use of 
NSAID‟S in patients with inflammatory bowel disease was 
associated with protective role against colorectal cancer.  
3) Adenomatous Polyp: The transformation rate of adenomatous 
polyps into carcinoma is around 0.25% per year.In adenomas with 
villous architecture (like villous and tubulovil lous adenomas), 
high grade dysplasias ,there is a likelihood of 50% transformation 
to malignancy.  
4) Endogenous Factors: Studies have shown that endogenous 
hormones, especially oestrogens may influence adenoma 
carcinoma sequence.Individuals with acromegaly also have 
increased risk. 
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MODIFIABLE RISK FACTORS 
1) Dietary Factors:  Person with high intake of fatty and cholesterol 
products,refined carbohydrates,red meat with little fibre intake are 
more likely to develop CRC..High fat intake enhances hepatic 
synthesis of cholesterol and bile acids which are converted to 
carcinogens by the intestinal bacteria. 
(16)
 
2) Obesity:  Overweight and lack of exercise with sedentary life 
style are more likely related to CRC development.  
3) Tobacco Smoking: It increases the risk for sessile serrated lesions 
and colonic carcinoma at earlier age.Even after cessation of 
smoking,cancer risk extends upto 20-30 years. 
4) Alcohol: Consumption of alcohol is associated with higher risk of 
colorectal cancer development.Tsong WH et al. study shows the 
association of alcoholism with development of CRC in younger 
age.
(17).
Acetaldehyde and other reactive metabolites of alcohol act 
as carcinogenic by production of free oxygen species and it also 
acts as solvent for penetration of other carcinogens.  
5) Radiation: Long term complication of therapautic irradiation to 
pelvic malignancies can cause colorectal carcinoma. 
(18)
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PATHOGENESIS:  
(5,23)
  
The combination of molecular events eventually leading to 
colonic adenocarcinoma is heterogenous with genetic and epigenetic 
abnormalities.Tumorigenesis is generally considered as a multistep 
process where in various genetic alterations occur,eventually being 
reflected in abnormalities of the cellular DNA content.Based upon the 
genetic background ,Pathways for sporadic CRCs can be classified into: 
a. Chromosomal Instability Pathway,which is activated in classic 
adenoma-carcinoma sequence 
b. Micosatellite Instability Pathway,associated with DNA mismatch 
repair 
c. CpG island methylator Pathway 
CHROMOSOMAL INSTABILITY PATHWAY 
The genes of interest involved in genetic alterations may be 
classified into three types:Oncogenes,tumor suppressor genes and DNA 
repair genes. 
Proto-oncogenes act by promoting cell proliferation.Mutation of 
these leads to abnormal oncogenic over-expression and increased 
activity of protein. In normal state,tumor suppressor genes inhibit cell 
proliferation.Its inhibition is lost when both the alleles are inactivated 
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by mutations and/or epigenetic changes.DNA repair genes help in 
controlling rate of mutation of other genes. 
(20)
 
APC MUTATION 
The adenoma-carcinoma sequence is most commonly initiated by 
bi-allelic APC tumour suppressor gene mutation.By studies of Otori et 
al 
(21)
,and Roncucci et al 
(22)
 .,APC mutations have been found in 
earliest lesion of pathway called microadenoma /aberrant crypt foci.APC 
is a key negative regulator of ß-catenin which is a component of Wnt 
signaling pathway. Normally,APC protein binds to ß-catenin and 
promotes its degradation.With loss of APC function, ß-catenin 
accumulates and translocates to nucleus forming a complex with DNA 
binding factor TCF and activates transcription of genes,including MYC 
and CYCLIN D1 which promotes proliferation.  
KRAS  MUTATION 
By various literatures including Bishehsari et al.,Another 
oncogene which occurs early in adenoma-carcinoma sequence is 
activating mutation of KRAS. 
(24) 
Among all the mutations in human cancers,RAS protein mutations 
are observed in approximately 15 to 20% of them.In some cancer 
types,its mutation frequency is higher.About 90% of pancreatic 
adenocarcinoma and cholangiocarcinoma express RAS point mutation. 
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50% is expressed by colonic,endometrial and thyroid carcinomas.About 
30% of lung carcinomas and myeloid leukemias contain RAS mutations.  
There are three RAS genes in human genome (HRAS, KRAS, 
NRAS). In colorectal carcinoma, mutations in KRAS are known to occur 
at frequency of 35-40% ,while NRAS mutations occur at frequency of 3-
4% and HRAS mutations at much lower rate of <1% of patients.  
MECHANISM OF ACTION OF KRAS ACTIVATION 
KRAS encodes a 21-kDa protein (ras p21)which is involved in 
signal transduction pathways critical for normal cellular proliferation 
and differentiation.
(20) 
These proteins are members of a family of 
membrane associated small G proteins binding to guanosine 
diphosphate(GDP) and guanosine triphosphate(GTP). When it is bound 
to GTP,ras protein becomes activated and gets inactivated when GTP is 
hydrolysed to GDP.They flip back and forth between these excited 
signal transmitting state (GTP bound) and quiescent state (GDP bound) 
normally.Thus,Growth factor stimulation of receptor tyrosine kinases 
leads to exchange of GDP for GTP and constitutive action to generate 
active RAS occurs by conformational changes.Subsequent stimulation of 
MAPK and PI3K/AKT arms of receptor tyrosine kinase downstreams the 
activation of cytoplasmic effectors and several other transcription 
factors that supports cell growth and proliferation. 
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RAS activation is transitory,as it has an intrinsic GTPase activity 
which is controlled by GTPase activated proteins(GAPs) thereby 
preventing uncontrolled RAS activity.Variety of distinct RAS point 
mutations identified markedly reduce these GAPs activity.Hence 
mutated RAS forms are trapped in GTP bound activated form and keeps 
on receiving continuous pro-growth signals. 
 
Fig-8 :Growth Factor Signaling Pathways With Ras Actvation  
 According to Vogelstein et al (23).,activation of K-ras occurs in 
35-42% of colorectal carcinomas.They conducted this study in 
172 colorectal tumor cases representing various stages of tumor 
development and looked for 4 genetic alterations namely RAS 
gene mutations and deletions of chromosomes 5,17 and 18.RAS 
mutations observed in 58% of larger adenomas >1cm size. 47%in 
carcinomas and 9% of adenomas <1cm size.Thse 4 genetic 
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alterations accumulated in a fashion which paralleled clincical 
progression of tumor.  
 By various literatures and COSMIC resource(25),there have been 
vaguely around 3000 identifiable K-ras point mutations in 
colorectal carcinoma.There are 61substitutions where the 
nucleotide change is still unclear.This COSMIC resource is the 
most comprehensive tool for exploring the impact of somatic 
mutations in human cancer.  
 Study by Brink M,et al.(26) ,have shown that commonest mutation 
hot spots are CODON 12 and CODON 13 of  EXON 2,with G>A 
transitions and G>T transversions being the predominant 
mutations.  
 The significance of finding out K-ras mutational status lies in the 
fact that it is one of the most important predictors of  targeted 
therapy using EGFR1 tyrosine kinase inhibitors.
(27)
 
 According to karapetis et al.,(28) As K-ras serves as mediator 
between extracellular ligand binding and intracellular signal 
transductions from EGFR to nucleus,its mutation would defer this 
pathway,thereby rendering EGFR inhibitors ineffective. 
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TP53: 
TP53, labelled
„
Guardian of genome
‟
 functions to regulate cell cycle 
progression,cellular senescence and DNA repair. P 53 inhibition leads to 
loss of mutation involving TGF-ßreceptors  which induces invasion and 
metastasis. 
Datas of Rodrigues et al,
(29) 
suggests that loss of function 
mutation in P53, which is about 50% of colorectal carcinomas occurs as a 
late event in adenoma-carcinoma progression. 
OTHER GENES 
 Mutations in BRAF (V600E) proto-oncogene is observed in 10% 
of CRC cases.(30).These mutations correlate to shorter survival 
rates 
 Identifiable tumor suppressor genes include SMAD2 and SMAD4, 
mutations of which allow for unrestrained cell growth.  
MICROSATELLITE INSTABILITY PATHWAY: 
(20)
 
Microsatellites are types of DNA with tandem repeats usually 
between 1 to 5 basepairs  repeated many times.In normal individuals,the 
length of microsatellite remains constant.These microsatellites are 
interspersed throughout the genome and are prone for errors during 
DNA duplication.The function of mismatch repair proteins(MMR) to 
correct these errors.In the absence of MMR function,microsatellite 
errors tend to accumulate.  
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Tumors with microsatellite instability(MSI) are further referred to 
as those exhibiting low levels or high levels of instability as MSI-L or 
MSI-H respectively.(31)Some microsatellite repeats are situated in 
coding or promoter regions of cell growth as like in encoding type II 
TGF-ß receptor and BAX pro-apoptotic protein.Mutation of TGF-ß 
receptor contributes to uncontrolled proliferation and loss of BAX 
increases survival of abnormal clones. 
Notable five human MMR genes are: 
 hMSH2 
 hMLH1 
 hPMS1 
 hPMS2 
 MSH6.    
The majority of those associated with HNPCC have germline 
mutations of either hMSH2 or hMLH1. 
CpG ISLAND METHYLATOR PATHWAY 
Epigenetic instability in CRC is reflected as hypermethylation of 
loci containing CpG islands.Toyota et al., study was the first one to 
describe these class of CRC with CpG Island Methylator 
Phenotype(CIMP).
(32)
 It has been proposed that aberrant DNA 
methylation arises during aging process by epigenetic drift leading to 
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overgrowth of tumorogenic cells.Histone modification and gene 
mutations involved in chromatin structure are all the postulates for this 
aberrant pathway
(33)
 Further sub-classification as CIMP–H when ≥3 
markers express methylation ,otherwise as CIMP-L.Study includes 
MINT1,MINT2,MINT3,MLH1 and p16
INK4a
as markers to define the 
CIMP .
(43) 
 
Fig-9: Molecular Pathogenesis Of Adenoma-Carcinoma Sequence 
GROSS APPEARANCE OF LESIONS  
Shimoda et al.
(54)
 in his study classified lesions based on 
endoscopic findings: 
Polypoid type Non-polypoid type 
Pedunculated 
Sessile 
Superficial elevated 
Completely Flat 
Depressed morphology 
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Fig 10: Macroscopic Classification Of Lesions  
HISTOLOGICAL SUBTYPES OF CRC AND ITS FEATURES 
ADENOCARCINOMA  
Common type of large bowel tumors are well to moderately 
differentiated adenocarcinomas having papillary or villoglandular 
configuration with variable amount of mucin secretion.The tumor cells 
consist of columnar and goblet cells with occasional presence of 
neuroendocrine cells and rarely the presence of paneth cells also as 
mentioned in the study by Shousa.S,1979 
(34)
.The carcinoma elicits a 
desmoplastic reaction and invasion may be seen extending through all 
layers into pericolic fat. 
The edge of tumor may show foci of residual polyp or 
hyperplastic change in glands,with altered mucin secretion referred to as 
“transitional mucosa”.The disordered glands at the advancing edge have 
been called as “tumor budding” which is associated with poorer 
prognosis within tumors of same staging .
(40)
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MUCINOUS CARCINOMA 
As the name suggests, these carcinomas contain large lakes of 
extracellular mucin with admixture of tumor cells. According to  
Connelly et al. 
(35)
 and several other studies, mucinous foci should be 
atleast 50%(half) of tumor mass.These tumours occur most commonly in 
rectum and comprises about 15% of CRCs. They are associated with 
high rates of microsatellite instability.  
MICROPAPILLARY PATTERN 
Micropapillae are present in lacunar-like spaces and exhibit 
„reverse polarity‟ with apical surfaces facing periphery than the center.It 
has a greater tendency for lymphovascular invasion and  lymphnode 
metastasis.A minimum of 5% of tumor with micropapillary feature is 
required for the diagnosis of this subtype.
(40) 
This subtype comprises 
about 20% of CRCs. 
SIGNET RING CARCINOMA 
It usually presents grossly as diffuse infiltration of wall and 
microscopically too tumor grows in diffuse fashion with most of the 
cells showing intracellular accumulation of mucin,which pushes the 
nucleus imparting a typical signet ring cell configuration.Pattern of 
spread is in the form of peritoneal dissemination and possibility of 
secondary deposits from primary from gastric or breast carcinoma 
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should always be ruled out before diagnosing i t as primary signet ring 
cell carcinoma.
(36) 
SERRATED ADENOCARCINOMA 
This is thought to arise from serrated adenoma neoplastic 
pathway,accounting for 7.5% of all colorectal carcinomas and upto 10-
15% of proximal located tumors acconding to a study by Makinen.
(37)
 It 
shows serrated pattern of growth with preserved polarity and no necrosis.  
MEDULLARY CARCINOMA 
(38)
 
Formerly called as „large cell carcinoma with minimal 
differentiation‟,now due to its organoid pattern, its being termed as 
“Medullary carcinoma”.Grossly they are bulky masses with expansile 
growth.Microscopically they appear as sheets of malignant cells with 
vesicular nuclei and prominent nucleoli ,along with intraepithelial 
lyphocytic infiltration. Studies by Thirunavukarusu P.et al
(39)
 confirms 
its high frequency association with MSI.  
SQUAMOUS DIFFERENTIATION 
In most of the cases, squamous component is associated with 
glandular components(Adenosquamous carcinoma),occasionally can be 
seen in pure form as squamous cell carcinoma.Williams GT ,et al
(41)
 
postulated that some of these squamous cell carcinomas may arise from 
areas of squamous differentiation of pre-existing polyps. 
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OTHER UNUSUAL FORMS 
 Basaloid/ Clear cell/ Hepatoid Carcinomas:  All these rare 
varieties resemble their origin of morphological 
counterpart.Immunohistochemical markers and biochemical 
markers like serum Alpha-fetoprotein will support the diagnosis.  
 Trophoblastic differentiation- Immunohistochemically hCG can 
be demonstrated in tumor cells.  
 Glassy cell carcinoma – Can be present in large bowel similar to 
its counterpart in uterine cervix
(42)
 
 Rhabdoid features –if present ,as in other sites signify aggressive 
behavior 
(40)
 
 Carcinosarcoma- This extremely rare form exhibit areas of 
typical adenocarcinoma merging with sarcoma.Cytokeratin 
positivity of sarcomatous elements is useful in establishing 
diagnosis. 
Neuroendocrine Differentiation 
It can manifest in various ways as  
1) According to Ulich et al., and other studies,it occurs as “scattered 
endocrine cells” in otherwise typical adenocarcinomas .
(44)
 This 
kind of occurence is more common post chemotherapy or 
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radiotherapy suggesting that these cells may be the induced 
changes  by these modalities.  
2) In „mixed composition‟ form with typical adenocarcinoma,  
admixed with a component of endocrine differentiation. 
3) As “Neuroendocrine carcinoma” with organoid appearance 
composed of larger cells and small cells, being positive for 
Neuron specific enolase and synaptophysin.  
IMMUNOHISTOLOGICAL AIDS 
Though the diagnosis of CRCs are established 
histomorphologically, some early malignancy that have penetrated via 
muscularis mucosae into submucosa and presence of scattered 
neuroendocrine cells,paneth cells or foci of squamous differentiation 
which is compatible with diagnosis of adenocarcinoma can be 
substantiated by the use of specific immunohistochemical markers 
(45) 
IHC MARKERS 
CK 7 and CK 20 
 Almost 80-100% adenocarcinomas typically show strong 
positivity for CK20.But in microsatellite unstable 
adenocarcinomas,there is a decreased expression of CD20. 
 CK 7 is infrequently expressed in colorectal carcinomas.Although 
upto 13% of cases can express CK7. 
(46)
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 Thus CK7-/CK20+ is the standard combination for diagnosing 
colorectal carcinoma. 
Mucin 
 Colorectal carcinomas can show aberrant expression of mucin 
,thus making it usefulness as markers.  
 Various mucins include MUC1,MUC2,MUC3,MUC4,MUC5AC 
and MUC6. 
 MUC1-transmembrane glycoprotein overexpressed in various 
carcinomas like breast,colon,prostate and lung.Al-Khayal et al., 
study show that it may be used as biomarker for detection of early 
as well as late CRCs. 
(47)
 
 MUC2-Primarily expressed in colorectal goblet cells.  
 MUC5AC- Predominantly expressed in mucus lining of stomach 
and lung.It is typically negative in CRC.If at all positive,a study 
by Betge J et al showed that Gain of aberrant MUC5AC and 
MUC6 expression was associated with favourable outcome of 
CRC. 
(48) 
CDX2: 
It represents intestinal differentiation and is positive in about 75 -
100% of colorectal adenocarcinomas.However its not specific and 
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positive staining can be other list of carcinomas showing intestinal 
differentiation.Yet, it can distinguish colorectal carcinoma extending 
into bladder from primary bladder carcinoma and Metastatic CRC from 
mucinous bronchoalveolar carcinoma.  
Villin 
Intestinal brush borders are highlighted by Villin and so it appears 
as diffuse cytoplasmic staining with brush border accentuation in 
colorectal carcinomas. 
(49)
 
OTHER ANTIBODIES 
 CARCINOEMBRYONIC ANTIGEN(CEA) 
 TUMOUR-ASSOCIATED GLYCOPROTEIN-72  (TAG-72) 
 FOLATE RECEPTOR –α (FR-α) 
These membrane bound glycoproteins are expressed in over 80% 
of colorectal carcinomas with relative low expression in normal mucosa 
as reported by Johnson et al
(50)
 and Jantscheff et al 
(51)
 studies. 
 HUMAN CHORIONIC GONADOTROPIN – Increased expression 
is associated with aggressive behavior of tumor.  
 Her2µ-EPIDERMAL GROWTH FACTOR 
 CATHEPSIN B 
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MISMATCH REPAIR PROTEINS 
For CRCs with deficiencies in mismatch repair proteins usually 
with characteristics of right sided location,<50 years of onset,lack of 
“dirty necrosis”, tumor infiltrating lymphocytes,with crohns like 
reaction - panel of four main proteins namely MLH1,MSH2,MSH6 and 
PMS2 can be used . 
GRADING OF ADENOCARCINOMA: 
(52)
--
  
( ANNEXURE II) 
STAGING SYSTEMS: 
Various staging systems for colorectal carcinoma to determine the 
extent of spreading are as follows:- 
 Duke‟s Classification Staging  & system of Astler and Collar  
 TNM  staging and prognostic stage groups by AJCC ( Annexure 
III & IV) 
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PROGNOSTICATION FACTORS 
Factors Good Prognosis Poor Prognosis 
Age  Very young and Very old 
age 
Sr.CEA Levels  >5.0 ng/dl 
Local extent Focal microscopic 
carcinoma restricted to 
mucosa /submucosa 
Beyond bowel wall and 
Metastasis 
Tumor margins Pushing margins  
Tumor budding  Isolated tumor cells or 
clusters >5 cells at 
invasive front 
Vascular 
invasion 
 ++ 
Pericolonic 
tumor deposits 
 ++ 
Perineural 
invasion 
 ++ 
Surgical 
Margins 
 Radial margin 
involvement 
Tumor type Medullary carcinoma Mucinous/signet 
ring/Anaplastic 
Angiogenesis  ++ 
Expressions of: HLA-DR/BCL2/ 
TGF-ßmutation  
MSI 
KRAS mutation 
Fascin/ pRb & P16/ hCG 
Allelic loss of chr.18 
Staging & 
grading 
 Increased staggings & 
grading 
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MOLECULAR STUDY OF K-RAS IN COLORECTARAL 
CARCINOMA 
 
In a cohort study by Zocche et al(2015).,
(55) 
mutational status of 
KRAS with 148 patients diagnosed with stage IV Colorectal carcinoma 
were analysed and treatment response with FOLFOX regimen were 
studied for a 6years period between 2008-2013.Mutational status of 
KRAS was determined by DNA extraction using QIAGEN kit, later on 
by PCR amplification and sequencing.The exclusion criteria being 
previous history of chemoradiotherapy and history of other malignancies 
within 5 years .Survival analysis was done by Kaplan-Meier analysis 
and comparison among groups were analysed using log-rank test. 
Among total of 148 patients,48(32%)had mutated KRAS and 
majority (77%)were at codon12 and (23%)at codon13.The Kaplan –
Meier survival analysis of individual subtypes of KRAS mutation 
showed that  G12D subtype seemed to be associated with poor prognosis 
in progression free survival,while no significant results were obtained in 
overall survival for other subtypes in their study population.  
In the present cohort study of Stage IV patients treated with 
FOLFOX regimen, it was observed that KRAS mutations were 
associated with high risk of recurrence,especially G12D mutations 
showed a worse clinicical outcome.Limitations of this study include 
inconsistent information when tracking lost patients due to transfer to 
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other regions and insufficient sample size.This multivariate analysis 
showed KRAS mutation as an independent negative prognostic factor for 
progression- free survival and concluded that it had an adverse impact 
on prognosis for metastatic CRCs. 
Al-Allawi et al (2012).,
(56) 
researched on KRAS gene-point 
mutational detection to determine its frequency in colorectal 
carcinoma.Study was done for two years with a total of 61 colectomy 
cases in Iraq population.Enrollment criteria for the study included 
colorectal carcinomas that are electively resected with no prior chemo 
and radio therapies.Sections were obtained from the tissue blocks  and 
the one which represented the tumor best was selected for study. DNA 
was extracted from the Formalin Fixed Paraffin Embedded (FFPE)tissue 
via QIAGEN kit;KRAS point mutation detection was carried out using 
KRAS STRIP ASSAY kit.These readymade strips contain allele specific 
oligonucleotide probes as an array of parallel lines which detected 10 
different KRAS mutations. 
There were 50 colorectal carcinoma cases fitting into enrolled 
criteria of which 24(48%) had KRAS mutations. The most commonest 
among them were G>T transversions and G>A transitions with 41.1% 
each and then G>C transversions with 17.2%. Codon 12 constituted the 
major (89.7%) whereby the 10.3% was by Codon 13. As observed with 
previous literatures,this study also showed that KRAS codon 13 
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mutations were less frequent than Codon12.There were also double 
mutations and triple codon mutations observed in same patients.These 
multiple mutations were seen in 8% of cases.This study did not show 
any significant correlation of KRAS status with age,gender and site of 
tumor,grading,TNM staging or lymphovascular invasion. The study 
concluded that KRAS mutations were common among Iraqi sporadic 
CRC cases with comparable frequencies of western countries.  
In the study of Irani Shemirani A et al (2011).,
(57) 
Profile of 
KRAS and MSI mutations in colorectal cancer by PCR analysis was 
performed,whereby examining the colorectal fresh tissues and DNA 
extraction using Qiagen kit was done. Further amplification by PCR was 
carried out using specific forward and reverse primers in which 493bp 
region of exon 2 and 402bp in exon 3 that comprises the mutational 
hotspots were amplified. The amplified DNA PCR product was then 
subjected to direct sequencing. KRAS gene in Exon 2 and Exon 3 
analysis were done in 95 cases with 48 tumor masses and 47 polyps. 
Patients with familial background –FAP/HNPCC were excluded. 
Out of those 48 tumors,they detected 6 mutations which includes 
5 mutations in codon 12 and 1 mutation in codon 13.In polyps, 2 
mutations were in codon 13 and 1mutation was in codon 12.All the 
KRAS mutations in codon 12 were G12A. Among the tumors detected 
with KRAS,all except one were in colon and that one was det ected in 
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rectum. But in contrast,among the polyps detected with KRAS mutation 
all yet one were in rectum and that remaining one was observed in 
colon.There was no significant correlation of KRAS mutation with the 
individual‟s clinical features harbouring the polyps or tumors.   
Furthermore,MSI status detection was done using pentaplex set of 
microsatellite markers.MSI was labeled when 1 or >1 marker was 
altered.The commonest MSI marker in the study population was NR-21. 
The study gave an inference of considering Gly12Asp in exon 2 as 
biomarker to prediagnose susceptible individuals before the progression 
of tumor. 
A review article by Federico A. et al (2009),
(58)
concluded that 
multiple methods are available for determining KRAS mutational status 
of tumor.All of these methods appear to have adequate clinical 
sensitivity to detect patient‟s unresponsiveness to EGFR inhibitors - 
cetuximab or panitimumab.  
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Various Methods used for testing KRAS mutations are 
summarized  as tabulation in this literature:- 
Methods of kras 
analysis 
Sensitivity,% of 
mutant alleles 
Comments 
Sanger sequencing 20% Gold standard but Time 
consuming 
Pyrosequencing 5-10% Ability to detect short PCR 
products; Detects all 
possible mutations and is 
inexpensive 
PCR Clamping method 1% Rapid, closed PCR system 
;But doesn‟t allow to 
control DNA quality and 
efficiency of PCR 
amplification 
Real Time PCR 1% Detects only most common-
7 mutation panels; Needs 
more tissue than for other 
methods , for analysis . 
Post –PCR fluorescent 
melting curve analysis 
using specific probes 
5-10% Detects all possible 
mutations; rarely there is 
difficulty in distinguishing 
between mutation types 
Bolton L et al (2015).,
(59 )
study on KRAS mutation assays 
comparing therascreen Qiagen and Cast PCR methods to determine 
correlation between both was conducted testing the presence of 7 KRAS 
mutations in codon 12 and 13-G12A,G12D,G12R,G12C, G12V,G13D. 
DNA was extracted from FFPE blocks of colorectal carcinoma having 
>50% of neoplastic cells by using Maxwell 16 FFPE plus LEV DNA 
purification kit DNA extracted was quantified by Nanodrop 
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sphectrophotometry. Further on,the samples were subjected to ARMS-
based therascreen assay and castPCR methods.  
Sensitivity was calculated as proportion of KRAS mutated tumors 
identified by cast PCR/proportion of KRAS mutation identified by 
therascreen,ignoring those mutations that are detected by castPCR but 
not in therascreen. Specificity was determined by Wild-type KRAS 
tumors identified by castPCR to proportion of Wild type tumors by 
Therascreen. Out of 99 samples,3 of them showed discrepancies between 
these two mutation detected methods on initial testing.Statistical 
sensitivity and specificity were 95%and 98% respectively.  
Sensitivity=(96/99)x10095%; Specificity= (61/62)x10098% 
Inference from this study is that there was good correlation 
observed between these two methods. Initial discrepancies between 
these methods were solved by re-testing.castPCR showed comparatively 
lower Ct(threshold value) than therascreen,hence it can pickup even 
tumors with little mutant DNA present.Study showed that castPCR is a 
reliable assay for KRAS testing in FFPE colorectal samples.  
Okayama N et al (2011).
(62) 
suggested the importance of DNA 
amplificability and amplicon size as important for success of mutation 
detection tests from FFPE samples. This study evaluated the DNA 
amplificability levels, effects of formalin fixation, deparaffinization and 
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storage time in paraffin blocks for achieving success rate in KRAS 
mutational analysis by dideoxy sequencing .19 FFPE CRC tissue 
samples  were obtained from a hospital in Japan during the period of 
2004-2009. 10% buffered formalin was used for fixation.Sections of size 
4µm and 10µm were used for H& E staining and DNA extraction 
respectively. Deparaffinization done with 1ml of xylene at 26
0
c 
incubation. Then they were centrifuged to obtain the pellets,followed by 
DNA extraction by QIAamp kit.  
Inorder to evaluate PCR amplificability of extracted DNA,12 
primer sets for 9 genes having various amplicon sizes were used.PCR 
product analysation was done by 3% agarose gel electrophoresis and 
stained by ethidium bromide.PCR products were purified by ExoSAP 
and terminator cycle sequencing kit was used for Sequencing.  
With 19 FFPE CRC samples,smaller fragments with size range of 
96-278bp were amplified with PCR,whereas amplification was difficult 
in  ≥278 bp,thereby indicating size of the amplicon and amplification 
property‟s significance to avoid DNA degradation. For PCR 
tests,although DNA recovery rate tended to be higher in 60 minutes 
xylene treatment than in 10minutes treatments,DNA extrac tion from 10 
min.of xylene itself is sufficient.These suggest that deparaffinization 
time may not have any effects on DNA recovery . Also datas suggested 
that neither fixation nor storage time affects DNA amplification.  
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Tan C et al ( 2012).,
(60) 
in their review study discussed on various 
methods of KRAS testing like Sanger sequencing with sensitivity of 20 -
30%,Pyrosequencing with 5% and non –sequencing methods like Real 
time PCR with HRMA having  5% sensitivity, RFLP with sequencing 
having 0.1% and COLD-PCR with sequencing having 1-2.5% 
sensitivities. Also concomitant analysis of other factors like 
BRAF,NRAS and loss of PTEN was recommended since KRAS 
mutations account for around 35% of nonresponsive patients that receive 
Anti-EGFR therapy as mentioned in Allegra CJ et al. (2009).
(116)
 In a 
retrospective consortium analysis among 1022 colorectal tumor DNA 
samples,40% harboured  KRAS mutation, 4.7%-BRAF mutation, 2.64% 
with Nras mutation and 14.5% with PIK3CA mutation. This study 
provided the information that there is a lower incidence of KRAS 
mutational frequencies in Asian population compared to American and 
European nations. 
This review study also mentioned about DNA fragmentation 
caused by improper formalin fixation,heterogenous somatic KRAS 
mutations, and influence of stromal cells causing False-positive KRAS 
mutational results.  
In a study by Aghagolzadeh P et al (2016).,
(61)
 in assessing 
molecular and cellular biomarkers of colorectal carcinoma,they have 
included RAS mutation studies as one of the diagnostic and predictive 
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markers inaddition to P53 ,Ki67,MSI,VEGF and DNA hypermethylation 
studies. Cancer related molecular and cellular markers could be 
classified as 4 categories:-Diagnostic markers,Prognostic markers, 
Predictive markers and surveillance markers. A few points stressing the 
importance of  KRAS mutational testing in colorectal carcinoma is 
mentioned in this study.Different point mutations at Exon 2 commonly 
in Codon 12 and 13 , mutations of codon 61 in Exon 3 lead on to 
constitutive activation of tumorigenic pathway .Therefore, any genetic 
disruption of KRAS gene is one of the crucial step in development of 
many carcinomas including colorectal carcinoma 
Andreyev HJ et al study (2001).,
(63)
 in „RASCAL-II‟ study have 
incorporated datas of 4268 patients at different stages of colorectal 
carcinoma from 42 different centres in 21 countries. Exclusion criteria 
for further analysis included those with missing age (n=203) and no 
information of Duke‟s staging (n=75).Perioperative deaths(n=76) are 
included . Also those patients providing datas only on codon 12 and not 
on codon 13 were excluded (n=49).This second „RASCAL‟ study has 
been so far largest study to examine KRAS mutational status in 
comparison with outcome of the patient.The purpose of the study of 
exploring mutation at different stages of Duke‟s suggests that this 
mutation is particularly aggressive in Duke‟s stage C with 50% 
association. This study added up more details to its first study of 
 
55 
„RASCAL‟ and explored further role of KRAS mutation at di fferent 
stages of colorectal carcinoma.  
Study explored the effects of KRAS mutation where they detected 
12 possible mutations on codon 12 & 13,with GlyVal on codon 12 
being seen in 8.6% of cases had statistically significant impact on 
Failure Free Survival (p-0.004) and overall survival    (p-0.008) 
Also,there is an suggestion from the observation that GlyVal 
mutation is not only important for progression of carcinoma but also 
might predispose to more aggressiveness in patients with advanced 
CRC. 
Study of Veldore VH et al.2014, 
(66)
 was a retrospective study in 
299 unselected incidental CRC patients visiting the hospital for clinical 
management during the year 2009-2013.This study demonstrated the 
KRAS genetic abnormalities as important findings in CRC of Indian 
population.Seven different somatic mutations in Exon 2 region of KRAS 
gene was analyzed in this study. DNA extracted from FFPE blocks of 
tumor tissue was then screened for 7 point mutations in Codon 12 and 
13 of KRAS gene using Therascreen KRAS PCR kit by Real time PCR. 
Statistical analysis was done to assess relationship between KRAS 
mutation status and variables like age,sex,tumor location and 
morphology. Patients were considered positive for KRAS mutation even 
if one out of 7 mutations was detected. 
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Results obtained were: Mean age of population was 55.9±12.8 
years.The majority of population was male(65.2%). Neither age nor 
gender does seem to influence mutational subtypes of codon 12 and 
codon 13. There was a predominance of  well-differentiated lesion 
(79.9%) ; Lesions primarily located in left side of colon(48.5%).KRAS 
mutation was obtained in 42.8% .Gly Val followed by Gly Cys,then 
GlyAsp was the order of frequency of the mutations.Chi-Square 
analysis showed that there was significant correlation between KRAS 
mutation and well differentiated adenocarcinomas compared to other 
subtypes. GlyAla mutation was higher in rectosigmoid region. KRAS 
mutation is one of the recognized predictive marker in metastatic 
colorectal carcinoma,thereby predicting its efficacy in Anti-EGFR 
treatment. 
Bengala et al (2010).,
(64)
 demonstrated that patients with KRAS 
mutation had decreased rate of complete responsiveness to concomitant 
chemoradiation with continuous infusion of 5FU with/without 
oxaliplatin and capacitabine compared to wild type of KRAS (7.4% vs 
19.2%). This study did a retrospective review of clinical outcome of 146 
locally advanced rectal cancer (LARC) cases treated with preoperative 
chemoradiotherapy and their KRAS, EGFR status. Fluorescence in situ 
hybridization (FISH) studies were performed on selected paraffin-
embedded sections having good tumor tissue for EGFR analysis.  
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KRAS gene analysis with 5µm thick sections obtained from FFPE 
blocks were transferred to an Eppendorf tube containing digestive bu ffer 
(proteinase K in 50m Tris, 1m EDTA,0.5% Tween20) with overnight 
incubation at 56
0
 c.PCR was carried out using commercial master mix 
with initil denaturation at  95
0
 c for 10min. was followed by 41 cycles 
,annealing at 52
0
 c for 1min and finally extension at 72
0
 c for 2min.Exon 
2 of KRAS was amplified using primers.Amplified products after 
quantifying with 2% gel electrophoresis was subjected to terminator 
cycle sequencer.This study concluded that EGFR and KRAS mutation 
status are neither predictive nor prognostic indicators for pathological 
tumor response in locally advanced cancer patients treated with prior 
chemoradiation. 
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Materials and Methods 
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MATERIALS AND METHODS 
In this study,we performed both prospective and retrospective 
data analysis of patients who were diagnosed to have colorectal 
carcinoma over a period of  2 years from August 2016 to August 
2018.The study been undertaken in Institute of Pathology,Madras 
Medical College and Rajiv Gandhi Government General 
Hospital,Chennai. 
SOURCE OF DATA  
During the study period,we received about 23,057 specimens for 
histopathological examination,of which 2603 cases belong to 
Gastrointestinal tract system .Out of 2603 specimens,268 specimens 
were lower gastrointestinal tract malignancies.In that 268 mali gnancy 
cases,250 cases were Adenocarcinoma of colorectal region which 
includes both colonoscopy guided small biopsy and resection specimens 
INCLUSION CRITERIA 
All Histopathologically proven cases of  Colorectal carcinoma  
EXCLUSION CRITERIA 
Samples of patients with prior history of neoadjuvant 
chemotherapy. 
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METHOD OF DATA COLLECTION: 
Sample size of  30 cases reported during the study period were 
taken for study.Detailed history regarding age,sex,type of procedure,site 
of tumor,imaging findings,any serological parameter if available were 
collected from surgical pathology records.Molecular detection of KRAS 
from the Formalin fixed paraffin embedded (FFPE)tissue blocks was 
done using Polymerase chain reaction (PCR) amplification and analysis 
by sanger sequencing. 
DNA EXTRACTION 
FFPE tissue blocks of biopsy proven colorectal carcinoma having 
the highest density of malignant cells are chosen by microscopic 
viewing of hemotoxylin and eosin stained slides.DNA extraction from 
theselected blocks were done using QIAamp DNA FFPE tissue kit (from 
Qiagen manufacturer).Steps are carried on following the manufacturer‟s 
guidelines: 
 Sections from blocks are cut with 5-10µm thickness and 
immediately sections are placed in a 2ml microcentrifuge tube and 
1ml of xylene added.Lid is closed and vortexed vigorously for 
10seconds. 
 Centrifuging is done at full speed for 2min. at room 
temperature.Later supernatant is removes by pipetting out,leaving 
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the pellet aside. 1ml of ethanol is added to pellet and mix by 
vortexing. 
 Again centrifuge for 2min and then remove the 
supernatant,incubate the tube at 37
0
/room temperature for 
10minutes with opened lid.  
 Now pellet is suspended with 180µl of buffer. 20µl proteinase is 
added and mixed by vortexing was done.Further incubations at 
56
0
c and 90
0
c ,each for 1 hour respectively been done.  
 Further more centrifugations by adding buffer to pellets are 
carried on and  transferred to lysate column; 
 Place the QIAamp MinElute column in a microcentrifuge 
tube,apply 20-100µl buffer ATE.Final centrifugation with buffer 
ATE for 5min.at room T
0
 yields the DNA. 
DNA QUANTIFICATION 
DNA yields were quantified by using  a Nanodrop 2000 
spectrophotometer and concentration in ng/µl is measured. 
PCR AMPLIFICATION 
After standardization using best performed primer,the test  was 
carried out with 30 samples with better DNA yield.The following 2 
primers are used: 
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Primers Sequence (5‟3‟) Product size 
FORWARD 
PRIMER 
GGTACTGGTGGAGTATTTGATAG 247 bp 
REVERSE 
PRIMER 
GGTCCTGCACCAGTAATATGC 247 bp 
Hot star Master mix was setup for the final reaction in PCR,which 
are tabulated later down.The reaction mixture was mixed well with 
1.65µl of DNA template being added to each tube.Final volume of 
reaction mixture was 25µl.The mixture was well centrifuged in a 
microcentrifuge for 1min and tubes were placed in 96 wells of 
thermocycler (Applied biosystems –manufacturer). 
Table Showing PCR Hot Start 
Reagent Volume 
PCR buffer 2.5 µl 
Forward primer 0.5 µl 
Reverse primer 0.5 µl 
DNTp‟s 2 .0 µl 
Taq polymerase 0.25 µl 
DNA 1.65 µl 
H2O 17.6 µl 
Total 25 µl 
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Thermal cycling conditions used for PCR 
Steps Temperature Time Cycles 
Denaturation 95
0
C 2min 1 
Annealing 95
0
C 
59.1
0
C 
72
0
C 
30 sec 
30 sec 
30 sec 
 
30 
Cooling 72
0
C 5 min 1 
Annealing begins at 95
o 
C and ends at 72
o
C ,lowered by 1
o
C for 
every 4 cycles until it reaching 59.1
o
C 
ANALYSIS OF AMPLIFIED TARGETS BY SEQUENCING 
The PCR product was checked for amplification using agarose Gel 
Electrophoresis. Then to 5µl of  amplified PCR product,2µl of Exosap 
was added and subjected to sequencing reaction in ABI 3500 Genetic 
sequencer(Applied biosystems) and analysed using basic search tool  
program with available standard reference sequences 
(https://m.ensembl.org) 
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STATISTICAL ANALYSIS 
The statistical evaluation was performed with IBM-SPSS 
statistical package for the social sciences version 20. An initial analysis 
of collected variables was performed. Then, Molecular expression of 
KRAS analyzed were correlated with clinical variables like age, gender, 
size and pathological variables like histological grade, stage and 
invasiveness of the tumor. Pearson Chi square test was used in analyzing 
these variables. In the present study, the P value below 0.05 is 
considered significant. 
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Results 
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                 OBSERVATION AND RESULTS 
In Institute of Pathology, the total number of biopsy specimens 
received for histopathology from August 2016-August 2018 were 23,057 
,out of which the total number of gastrointestinal tract specimens 
include 2603and 268 of specimens were lower GI tract malignancy.The 
number of colorectal carcinomas enrolled in this study was 30 cases out 
of 250 cases of colorectal adenocarcinoma.  
Histomorphological and molecular analysis of KRAS expression 
were studied and compared with literatures. For the (n=30)cases, results 
obtained are as follows: 
AGE WISE DISTRIBUTION OF COLORECTAL 
CARCINOMA 
Table:1 
Table: 2 
Age range (in years) Frequency Percent(%) 
<40 5 16.6 
41-50 3 10.0 
51-60 11 36.7 
61-70 9 30.0 
71-80 2 6.7 
Total 30 100.0 
 n Minimum Maximum Mean Std. Deviation 
AGE (years) 30 24.00 80.00 55.20 13.95905 
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The highest incidence of CRCs were in the age group of between 
51-60 years(36.7%),followed by 61-70 years(30%).The mean age of 
presentation was 55.2 years.The youngest age of presentation in our 
study was 24 years and oldest age presented was 80 years.  
 
Fig-1 : Age-wise distribution of Colorectal Carcinoma (n=30)  
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GENDER WISE DISTRIBUTION OF COLORECTAL 
CARCINOMA 
Table:3 
Gender Frequency Percent (%) 
Male 17 56.7 
Female 13 43.3 
Total 30 100.0 
From the above table, it is observed that incidence of colorectal 
carcinoma in our study was comparatively more common in males  
(56.7%) compared to females(43.3%).  
Male :Female ratio observed was 1.3:1  
FIG2 : Gender wise distribution 
 
 
 
69 
SITE WISE DISTRIBUTION OF COLORECTAL 
CARCINOMAS: 
Table:4 –Showing distribution of tumor in various sites of colon and 
rectums 
Site Frequency Percent(%) 
Ascending colon(right sided) 8 26.67 
Hepatic flexure 2 6.67 
Transverse colon 1 3.33 
Splenic flexure 1 3.33 
Descending colon(Left sided) 1 3.33 
Sigmoid colon 6 20.00 
Rectum 11 36.67 
Total 30 100.00 
FIG 3: Site wise distribution of tumor 
 
From the above pie chart ,it is inferred that majority of colorectal 
malignancy cases occurred in Rectum with 11 cases  (37%), followed by 
ascending colon with 8 cases(27%). 
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GROSS FEATURES OF COLORECTAL CARCINOMA 
Table:5- depicts various types of gross lesions of colorectal tumor 
Grosslesion Frequency Percent (%) 
Ulcerated 3 10.00 
Ulceroproliferative 16 53.33 
Infiltrative  growth 4 13.33 
Proliferative 2 6.67 
Nodular 2 6.67 
Polypoidal 3 10.00 
Total 30 100.0 
Fig-4: Gross Lesions Of Colorectal Carcinoma 
 
The above table and pie chart shows the gross features of 
colorectal adenocarcinoma. 
The commonest gross feature noticed is the  Ulceroproliferative 
type of growth (53%),followed by infiltrative growth (13%).  
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SIZE OF LESION 
Since there is no significant cut-off size of prognostication 
significance, roughly % of cases of size less than and more than 6cm is 
taken for comparison purpose. 
 
From the above chart,it is observed that about 50% of tumours 
were <6cm and another half of the percent of tumours were >6cm.  
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HISTOLOGICAL SUBTYPES OF COLORECTAL 
CARCINOMA 
Table 6: Tabulation shows the histological variants of colorectal 
tumors of our study 
Histological subtypes Frequency Percent 
Conventional  adenocarcinoma.  27 90.0% 
Mucinous adenocarcinoma 3 10.0% 
Total 30 100.00% 
Observation made from the above  table shows that 90% of cases 
were Conventional adenocarcinoma and 10% were mucinous type.The 
upcoming chart also depicts the same. 
 
Fig 6: Histological subtypes of colorectal cancer  
 
 
73 
HISTOPATHOLOGICAL PATTERN 
Table 7-showing Various patterns in histopathology 
Fig:7  Chart Shows various HPE patterns in colorectal carcinoma  
 
The above datas suggest that in colorectal adenocarcinoma,the 
major histomorphological pattern of tumor cells were Glandula r 
configuration seen in 18 cases(60%) followed by 13% each by papillary 
configuration and then in sheets.Pattern to some extent can determine 
the grading based on differentiation of tumor, as in well differentiated 
adenocarcinoma mostly maintains glandular or villoglandular pattern.  
Pattern/configuration Frequency Percent (%) 
Glandular 18 60.00% 
Papillary 4 13.33% 
Villoglandular 2 6.67% 
Sheets/nests 4 13.33% 
Others 2 6.67% 
Total 30 100.00% 
 
74 
GRADING OF ADENOCARCINOMA-USUAL TYPE: (N=27) 
Table:8 shows % of cases in various histological gradings  
Grade Frequency Percent(%) 
Well differentiated 5 18.5% 
Moderately differentiated 18 66.7% 
Poorly differentiated 4 14.8% 
Total 27 100.0% 
 
Fig-8 chart depicting % of colorectal adenocarcinoma showing various 
degrees of grading: 
 
Thus it was observed that among the 27 adenocarcinoma cases, 
majority of them (67%) was moderately differentiated, 19% was well 
differentiated grade and 15%  was poorly differentiated grade.  
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T -STAGING 
Table:9 shows frequency of cases presenting with various T stages 
Stage Frequency Percent (%) 
T1 1 3.3 
T2 2 6.7 
T3 1 3.3 
T4 26 86.7 
Total 30 100.0 
 
Fig:9 charts showing % of cases in various T stages: 
 
From the graph above with T-stages as x-axis variables and % of 
cases representing in Y axis, it is seen that 87% of cases belonged to T4  
stage. 
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LYMPHOVASCULAR & PERINEURAL INVASION 
In this study,10 cases showed lymphovascular invasion and one 
adenocarcinoma case showed perineural invasion 
LYMPHNODE STATUS 
Table:10 shows the lymphnode status in colorectal observed 
carcinoma cases. 
Lymphnodes Frequency Percent (%) 
Metastasis 10 33.3% 
Reactive 16 53.3% 
No nodes 4 13.3% 
Fig:10 showing % of cases with variable status of lymphnodes in 
colorectal carcinoma 
 
It is seen that 16 cases (54%) of lymphnodes showed reactive 
hyperplasia, whereas 10 cases(33%) of them showed metastatic 
carcinomatous deposits. In around 13% of cases nodal status cannot be 
assessed. 
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ASSOCIATION OF AGE WITH HPE DIAGNOSIS 
Table:11 Crosstabulation of Age distribution with Subtypes of tumor 
Age 
group 
Infiltrating adenocarcinoma Mucinous 
adenocarcinoma Well Moderately Poorly 
N  (%) N(%) N(%) N(%) 
20-30 0(0.0%) 1(5.6%) 3(75.0%) 0(0.0%) 
31-40 0(0.0%) 1(5.6%) 0(0.0%) 0(0.0%) 
41-50 1(20.0%) 1(5.6%) 1(25.0%) 0(0.0%) 
51-60 1(20.0%) 9(50.0%) 0(0.0%) 1(33.3%) 
61-70 3(60.0%) 4(22.2%) 0(0.0%) 2(67.7%) 
71-80 0(0.0%) 2(11.1%) 0(0.0%) 0(0.0%) 
Fig:11 Age wise distribution of subtypes of adenocarcinomas 
 
The current study shows that most of the cases fall under the age group 
of 51-60 years and among them majority of them are moderately differentiated 
grade.In older age group>60 years also moderately differentiated grade is more 
common than other two grades.In individuals <50 years, both poorly 
differentiated  and moderately differentiated grades  are evenly distributed,with 
well differentiated grade being at lowest occurance. 
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ASSOCIATION OF GENDER WITH HPE DIAGNOSIS 
Table 12: Comparison of Gender with subtypes of tumor 
Fig-12: Cylindrical chart depicting correlation of gender with various 
types and grades of colorectal carcinoma.  
 
   From above observation,it is seen that among 
Men,Adenocarcinomas occurred with majority being moderately 
differentiated grade,followed by poorly differentiated and well 
differentiated grades.There were also 3 cases of mucinous carcinoma 
among male gender category.In females also, moderately differentiated 
grade comprised highest category than others.  
Sex 
Well.diff Moder. Poorly 
Mucinous 
adenocarcinoma 
N(%) N(%) N(%) N(%) 
MALE 3(60.0%) 7(38.9%) 4(100%) 3(100.0%) 
FEMALE 2(40.0%) 11(61.1%) 0(0%) 0(0%) 
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CORRELATION OF TUMOR SIZE WITH STAGE OF 
TUMOR 
Table 13:Size and T stage Crosstabulation 
Size(in cm) 
T stage 
Total 
T1 T2 T3 T4 
1-5 
1 2 1 11 15 
(6.7%) (13.3%) (6.7%) (73.3%) (100.0%) 
6-10 
0 0 0 14 14 
(0%) (0%) (0%) (100%) (100%) 
>10 
0 0 0 1 1 
(0%) (0%) (0%) (100%) (100%) 
Pearson Chi-Square= 4.615,p=0.594 
Fig 13: Bar diagram demonstrating T stage comparison with size of tumor. 
 
Most of the tumors ,about 26 cases fall under T4 staging with 
tumor invasion into serosa and periserosal pad of fat.Of which 14 cases 
were having the size in the range of 6-10cm,11 cases fall in 1-5cm size 
and 1 cases with >10 cm .And highest number of cases of all stages were 
in the size range of 1-5cm.There was no significant correlation between 
size and stage of tumor (p=0.594).  
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CORRELATION OF TUMOR GRADE WITH STAGING 
In our study ,it was inferred that majority of T4 cases (17 cases) 
falls in moderately differentiated grade; 1 case of T3 stage tumor was a 
poorly differentiated ; All T1 cases were well differentiated and in T2 
tumors 50% were well-differentiated. 
Thus earlier stage cancers were mostly well differentiated in our  
study.There is no correlation between grade and stage of tumor (chi 
square = 13.994 p=0.123).  
 
Fig 14:Chart shows the correlation between T staging and histological 
grading. 
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EXPRESSION OF KRAS MUTATION BY PCR & SEQUENCING 
Molecular expression of  KRAS by PCR amplification and sanger 
sequencing method is detected for the Codons 12 & 13,in Exon 2. 
The following mutations are screened in this assay:  
GLY12ALA(G12A),GLY12ASP(G12D),GLY12ARG(G12R), 
GLY12CYS(G12C),GLY12SER(G12S),GLY12VAL(G12V), 
GLY13ASP(G13D) 
Table 14: showing KRAS expressional status 
KRAS  MUTATION Frequency Percent (%) 
Detected 5 16.7% 
Not Detected 25 83.3% 
Total 30 100.0% 
Fig 15:  Pie chart showing kras mutated and wild types  
  
In the study,it was observed that 5 cases (16.7%) showed KRAS 
mutation and remaining 25 cases(83.3%) were KRAS Wild type.  
 
82 
CORRELATION OF HPE DIAGNOSIS WITH KRAS EXPRESSION 
Tab:15  HPE Diagnosis & KRAS Mutation Correlation 
Grade 
KRAS  mutation 
Total 
Detected Not detected 
Mucinous Adenoca 2(40.0%) 1(4.0%) 3(10.0%) 
Well Differentiated 1(20.0%) 4(16.0%) 5(16.7%) 
Moderately Differentiated 2(40.0%) 16(64.0%) 18(60.0%) 
Poorly Differentiated 0 (0%) 4(16.0%) 4 (33.3%) 
Total 5(100.0%) 25(100.0%) 30(100.0%) 
Pearson Chi-Square=6.640;  P=0.084 
Fig 16 :Molecular KRAS Expression status with HPE diagnosis of tumor. 
 
As seen from the above clustered cylinder chart, 40% (2 cases) of 
mucinous adenocarcinoma showed KRAS mutation; 20%(1 case) of well 
differentiated adenocarcinoma showed KRAS positivity, 40%(2 cases) of 
moderately differentiated adenocarcinoma showed KRAS positivity.There 
was no significant statistical correlation between grading of 
adenocarcinoma and KRAS expression as p value >0.05 (p=0.084).  
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CORRELATION OF AGE WISE DISTRIBUTION OF KRAS 
EXPRESSION 
Table 16 :shows KRAS expression status with that of age distribution  
Pearson Chi-Square=3.091 p= 0.686 
Fig 17: chart depicting correlation of kras mutational status with age  
 
Among the 5 KRAS mutation positive cases, 3cases belonged to 
age group of 51-60 years and 2 cases fall in 61-70 years age group.There 
was no statistical correlation seen between KRAS expression and age of 
the patient (p=0.686).  
Age Group 
KRAS Mutation 
Total   
No.of 
cases(%) 
Detected Not Detected 
No.of 
cases 
Percent% 
No.of 
cases 
Percent% 
20-30 Years 0 0% 4 16% 4(13.3%) 
30-40 Years 0 0% 1 4% 1(3.3%) 
41-50 Years 0 0% 3 12% 3(10%) 
51-60 Years 3 60% 8 32% 11(36.7%) 
61-70 Years 2 40% 7 28% 9(30%) 
Above 70 Years 0 0% 2 8% 2(6.7%) 
Total 5 100.00% 25 100.00% 30(100%) 
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CORRELATION OF KRAS EXPRESSION WITH GENDER 
Fig 18:  Chart showing the correlation between sex amd KRAS 
expression 
 
From the above chart, it was observed that among the KRAS 
mutated types, 60% were females and 40% were males.No statistical 
correlation was obtained between KRAS expression and gender.(Pearson 
Chi-Square=0.679 ; p= 0.410). 
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CORRELATION BETWEEN KRAS EXPRESSION AND 
TUMOR LOCATION 
Table 17: Upcoming table conveys the association between KRAS 
expression status with the various locations of colorectal carcinoma 
Fig 19: chart showing expression of KRAS at various tumor locations.  
 
In this study,it was observed that 60% of KRAS mutation detected 
cases were ascending colon growth(right sided colon) and 40% of them 
were rectal growth. No statistical correlation obtained between these 
two variables (Pearson Chi-Square=0.429  p= 0.807). 
SITE 
KRAS Mutation 
Total  
No.of 
cases(%) 
Detected Not Detected 
No.of 
cases 
Percent% 
No.of 
cases 
Percent% 
Asc.colon 3 60% 5 20% 8(26.7%) 
Hepatic flexure 0 0% 2 8% 2(6.7%) 
Transverse colon 0 0% 1 4% 1(3.3%) 
Splenic flexure 0 0% 1 4% 1(3.3%) 
Desc.colon 0 0% 1 4% 1(3.3%) 
Sigmoid colon 0 0% 4 8% 4(6.7%) 
Rectum 2 40% 11 44% 13(30%) 
Total 5 100% 25 100% 30(100%) 
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ASSOCIATION OF SIZE DISTRIBUTION WITH KRAS 
EXPRESSION 
Table 18:  Showing the distribution of size with KRAS expression 
SIZE 
KRAS detected KRAS not detected 
N % N % 
1-5 cm 2 40.0% 12 48.0% 
6-10 cm 3 60.0% 12 48.0% 
>10 0 0.0% 1 4.0% 
Total 5 100.0% 25 100.0% 
Chi square 0.377 ; p= 0.828 
Fig 20: Chart displaying the KRAS expression in varying sizes of 
tumor (in Cm) 
 
The above bar diagram represents that most of the cases fall under 
age group of 6-10 years,with 3 cases showing KRAS mutation and 12 cases 
are of KRAS wild type. Remaining 2 KRAS mutated cases come under age 
category of 1-5 years. Correlation between Tumor sizewith KRAS 
expression was found to be of no statistical significance (p=0.828).  
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CORRELATION OF “T” STAGING WITH KRAS 
EXPRESSION 
Table19: shows the association between KRAS expression with the 
depth of invasion of tumor (‘T’ staging) 
T stage 
KRAS Detected KRAS not detected 
N % N % 
T1 0 0.0% 1 4.0% 
T2 1 20.0% 1 4.0% 
T3 0 0.0% 1 4.0% 
T4 4 80.0% 22 88.0% 
Total 5 100.0% 25 100.0% 
Chi square = 2.031; p= 0.730 
Fig 21 :Showing Depth of invasion (‘T’ Staging) with KRAS  
expression status 
 
Most of KRAS mutated types (80%) were T4 stage -ie.,shows 
invasion into serosa and periserosal fat. Other 20% of KRAS mutated 
type falls under T2 stage invading the muscularis propria.  
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CORRELATION OF ANGIOLYMPHATIC INAVASION 
WITH KRAS EXPRESSION 
Table 20:gives the datas about correlation between angiolymphatic 
invasion of tumour with KRAS molecular expression: 
LV Invasion 
Detected Not detected 
N % N % 
LV+ 1 20.0% 9 36.0% 
LV - 4 80.0% 16 64.0% 
Total 5 100.0% 25 100.0% 
Pearson chi square =0.480 ;p= 0.787. 
Fig 22: Depiction of KRAS mutational status with lymphovascular invasion 
 
The above pyramidal chart gives us the inference that in our 
study,Angiolymphatic invasion is seen in 20% of KRAS mutation 
detected cases and 36% of KRAS wild type showed Lymphovascular 
invasion.There was no significant correlation between angiolymphatic 
invasion of tumor with KRAS expression.(p=0.787). 
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LYMPHNODE STATUS ASSOCIATION WITH KRAS 
EXPRESSION 
Table 21 :Conveys the lymphnodal status of tumor with KRAS 
expression 
Lymphnode status KRAS detected KRAS wild type Total 
Metastasis 1 (20%) 9 (42.9%) 10 (38.5%) 
Reactive 4 (80%) 12 (57.1%) 16 (61.5%) 
Total 5 (100%)s 21 (100%) 26 (100%) 
Pearson chi square = 0.891 P= 0.640 
Fig 23 : Lymphnodal status with KRAS expression in tumor tissue 
 
    In our study, among the KRAS Mutated cases only one case 
showed  lymphnode metastasis and other 4 showed features of reactive 
hyperplasia .Majority of cases  (21 cases) fall under KRAS wild type. 
No significant correlation was seen between these two variables,as 
p=0.640. 
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GROSS IMAGES 
 
 
 
 
Fig1:Proliferative growth in 
Rectosigmoid region 
Fig2: Ulceroproliferative lesion in 
Proximalcolon 
Fig 3: Mucinous carcinoma of 
Proximal colon 
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HISTOPATHOLOGY IMAGES 
 
Fig 4: Infiltrating adenocarcinoma-well Differentiated type(100x) 
 
Fig 5: Infiltrating adenocarcinoma-Moderately differentiated 
type(100x) 
Fig 8: Muscle invasion by tumor cells 
(400x) 
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Fig 6:Poorly differentiated Adenocarcinoma(400x) 
   
Fig 7:Adenocarcinoma-showing 
muscularis propria invasion (100x) 
 
Fig 8: Muscle invasion by  
tumor cells (400x) 
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Fig 9: Mucinous adenocarcinoma of colon 
 
 
Fig 10: Gel electrophoresis showing amplified DNA –PCR 
product 
 LANE 3,6,7 –AMPLICON OF PCR PRODUCT at 247bp 
 LANR 11--100bp LADDER 
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Positive (Bx.No: 7174)-KRAS MUTATED: 
 
 
 
 
 
 
 
Negative-KRAS WILD TYPE: 
 
Fig 11: Positive KRAS 
Mutation in 
    Sanger sequencing –G>A in 
codon 12 
Fig 12: Negative-KRAS wild  
type 
in codon 12 &13  
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DISCUSSION 
Colorectal carcinoma has now become one of the commonest 
cancer worldwide.As by various literatures,like Guraya et al(2006).,
(65) 
there is an evidence of a paradigm shift in its incidence among younger 
people < 50 years,as compared to old age due to various riskfactors ,to 
ascertain ,dietary factors with high animal protein and non modifiable 
familial risk factors owing to genetic alterations.Hence there is necessity 
for early diagnosis with the aid of evolving technologies and molecular 
assays . 
As Rajiv Gandhi Government General hospital is a tertiary 
referral centre,we receive a wide range of lower gastrointestinal 
malignancies which was around 268 cases during our study period of 2 
years,of which 250 were proven to be colorectal adenocarcinomas.  
In view of due significance of molecular assays in both 
prognostication and theranostication ,present study is done to analyse 
the KRAS expression in colorectal carcinomas and 30 FFPE blocks were 
studied for KRAS expression which was correlated with its 
clinicopathological variables. 
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AGE WISE INCIDENCE OF COLORECTAL CARCINOMAS 
The mean age of presentation in this study was 55.2 years ±13.95. 
This is in concordance with various studies of  Veldore VH et al,2014
(66)
 , 
Nekalson et al,2008 
(67)
 and Devadass clement et al,2016 
(68)
 
Table 1: Comparison of  Mean age with various studies  
In most of the age groups,moderately differentiated 
carcinoma(Grade 2) was the commonest Grade.A study by T.Patra et 
al.2018 
(69)
 also showed similar finding.  
GENDER WISE COMPARISON  
The incidence of colorectal carcinoma in our study was more in 
males (56.7%) compared to females(43.3%) and male:female ratio was 
1.3:1 .This was in concordance with other studies by Quddus et al. 
2012 
(70)
 ; peedikayil et al .2009 
(87) 
Table-2: Comparison showing  Male: Female ratio  
Studies Male:Female ratio 
Quddus et al,2012 1.5:1 
Peedikayil et al,2009 2.1:1 
Current Study 1.3:1 
Studies Mean age of presentation 
Veldore VH et al,2014 55.9 ± 12.8 
Nekalson et al,2008 58.2 ± 12.5 
Devadass clement et al,2016 52.3 ± 13.2 
Current Study 55.2 ± 13.9 
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These studies shows that females were affected at lower rates and 
5 year survival rate is also better than males, possibly attributed to the 
oestrogen hormones.The risk of post-menopausal women becomes the 
same as that of  men at that age group.  
HISTOLOGICAL SUBTYPES OF CRC 
In the present study,adenocarcinoma-usual type comprised 90% 
and 10% by mucinous type. This is in par with a study by Fatemeh 
Hajmanoochehri et al.2014 
(71)
 and Manmeet kaur Gill et al.2011
(73)
  
where majority of cases included conventional type of  adenocarcinoma.  
Table:3 showing frequencies of adenocarcinomas in various studies  
Studies Conventional adenocarcinoma % 
Fatemeh Hajmanoochehri et al  87.5% 
Manmeet Kaur Gill et al 77.5% 
Current Study 90% 
LOCATION OF CRC 
According to many literatures,its seen that part of colon distal to 
Splenic flexure were considered to be left sided colon and those 
proximal to splenic flexure were taken as right sided colon. Rectum was 
the highest site of occurance of carcinoma with11 cases(37%) in present 
study; This in in concurrence with other studies  by T.patra et al.2018 
(69)
  , where 46.2% of carcinomas occurred in rectum and Fatemeh 
Hajmanoochehri et al.2014 
(71)
 , where 55% were rectal carcinoma. 
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Table 4- shows the commonest tumor location incomparison with other 
studies 
Studies 
Jung MK  
et al. 
(72)
 
T.Patra  
et al.
(69) Current Study 
Commonest 
site(%) 
Left colon 
(66.2%) 
Left colon  
( 63.1%) 
Left colon(60%) 
The right and left sided colon carcinomas differ in presentation of 
symptoms and aggressiveness .Right sided colonic carcinomas present 
with bleeding,anemia and is more aggressive than left sided colonic 
cancer.Left side colonic cancer presents usually as palable obstructive 
mass. 
COMPARISON OF HISTOLOGICAL GRADES OF CRC 
In current study,most of the cases were of to moderately 
differentiated grade (66.7%), and this is in concordance with a study by 
Uzma nabi et al.2010 
(74)
 , however were discordant as compared with 
studies of Manmeet Kaur Gill etal.2011
(73) 
and Veldore et al. 
(66) 
Table -5, shows % of various histological grades in different studies 
Grades 
Well diff 
(Gr-I) 
Mod.diff 
(Gr-II) 
Poorly diff 
(Gr-III) 
Uzma nabi et al 15% 62% 23% 
Manmeet Kaur Gill et al 51.6% 41.94% 6.4% 
Veldore et al 80% 13% 17% 
Current Study 18.5% 66.7% 14.8% 
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Grossly Ulceroproliferative lesions were commonest (53.3%) in 
the present study and Histologically, glandular pattern were predominant 
in tumors with 60% .Angiolymphatic invasion was observed in 10cases 
and 1 case showed perineural invasion 
T staging observation in comparison with other studies -Table 6 
depicts it. 
Stage T Carvalho et al.2017
(75)
 Balta AZ et al.2014 
(76)
 
Current 
Study 
T1 2% 3% 3.3% 
T2 10% 16.6% 6.7% 
T3 66% 69.2% 3.3% 
T4 22% 10.5% 86.7% 
In the current study, majority of cases (86.7%) fall in T4 
stage,with invasion into serosa and periserosal fat. This was in 
discordance with other studies by Carvalho et al. and Balta AZ et al., 
whereby T3 stage was present in majority of cases ,as observed from the 
table above. 
It is also observed from the present study that larger the size of 
the tumor ,there is a higher tendency of tumors to fall in Stage T4 as 
compared to lesser size. In Size distribution of  1-5 cm,out of 15 cases 
 11 cases(73.3%) were T4 stage ,Under 6-10 cm range  all 14 
cases(100%) were T4 stage, in >10cm size,only one case presented 
which also falls in T4 stage.  
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        From the study proposed by Balta AZ et al. 
(76)
, it was found that 
progression of tumor stage was accompanied by the increase in tumor 
size. 
MOLECULAR EXPRESSION OF KRAS BY PCR AND 
SANGER SEQUENCING METHOD 
Initially there were some difficulties in DNA extraction and 
isolation from the FFPE blocks selected for PCR assay .Around 5 blocks 
from which DNA extraction done proved to be in vain owing to poor yield 
of DNA quantity and hence these samples were rejected.After optimization 
of procedures, 30 other FFPE blocks were subjected to DNA isolation and 
PCR processing .Most likely attribute to poor DNA yield and failure in 
seqsequent steps could be the DNA fragmentation. 
(77,78)
 
It is postulated in the study by Domagala P et al.2012 
(79)  
that 
DNA fragmentation is caused by formation of DNA –protein cross links  
and deactivation of nucleases over time in formalin solution.  
In Present study, 5 out of 30 cases (16.7%) showed KRAS 
mutation and other 25 cases (83.3%) were of KRAS wild type. Among 
the 5 mutated KRAS cases all of them showed mutational changes in 
Codon 12 . 
Present study revealed no significant correlation between KRAS 
mutations and clinicopathological variables like age ,gender,site and 
size of tumor.Also T staging and grading of tumor,angiolymphatic 
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invasion ,lymphnodal status exhibited no signification correlation with 
KRAS mutation (p>0.05).  
COMPARISON OF KRAS MUTATED FREQUENCIES 
In a study of KRAS mutation in colorectal cancer by Niraj 
Kumari et al.2013
(80)
 made on Indian population, 18.5% were KRAS 
mutated types and it also showed that Codon 12 had higher frequencies 
of mutations(64.7%) than codon 13(35.3%). It was in concordance with 
the present study frequencies too.  
From Patil H et al .2013 
(81)
 study in Indian cohort‟s KRAS 
mutation analysis ,it was observed that KRAS mutations was found in 
20.5% .There was significant association (p<0.05) between KRAS 
mutations ,age and tumor differentiation; Whereas no significant  
association was observed between KRAS mutations and gender 
(p>0.05%) 
Sameer et al. 
(82)
 study was done to identify KRAS gene 
mutations in colorectal cancer patients among kashmiri 
population.Tissue samples were collected from series of 53 patients 
undergoing respective surgery for CRC.Results showed that 22.64% of 
population  presented with KRAS mutations with 61.5% occurring in 
codon 12 and 38.5% in codon 13. KRAS mutations in both codon 12 and 
13 were common in mucinous type of carcinoma (38.1%) compared to 
non mucinous type (15.2%). This was not in concordance with current 
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study where KRAS mutation in mucinous carcinoma type was 40% and 
remaining 60% by non mucinous adenocarcinomas. 
AGE DISTRIBUTIONAL CORRELATION WITH KRAS 
MUTATIONAL STATUS 
In the current study,among 5 KRAS mutation positive cases,3 
cases fall in 51-60 years and 2 cases under 61-70 years, with all cases > 
50 years of age. 
Thus, it was observed that older the age, higher is the frequency 
of KRAS mutation compared to younger age group from our study;  
Though there was no significant correlation found between these two 
variables. 
As per Liu et al. 
(84)
 study,Mean age of presentation of mutated 
KRAS was 60.5± 11.7 years and there was no significant correlation 
between age and KRAS mutational status in their study. 
CORRELATING THE KRAS MUTATIONAL STATUS WITH 
GENDER: (AS SHOWN IN TABLE-7) 
Studies 
Male  
(KRAS mutated%) 
Female  
(KRAS mutated %) 
Phipps AI et al 
(83)
 45% 55% 
Zocche et al 
(55)
 44.7% 55.3% 
Niraj Kumari et al 
(80)
 70.6% 29.4% 
Current Study 40% 60% 
 
105 
Thus in observation with other studies by Phipps AI et al,Zocche 
et al .,our study showing higher incidence of KRAS mutation among 
female gender appeared to in concordance;Yet few studies like niraj 
kumari et al showed male predominance (70.6%) of KRAS mutation.  
CORRELATION OF  KRAS MUTATION EXPRESSION WITH 
LOCATION OF TUMOR 
The current study revealed that 60% of KRAS mutation detected 
were ascending colonic growth and 40% of them were rectal 
growth.There was no statistical correlation between site of tumor and 
KRAS mutation (p=0.807) . As there were thoughts from few literatures 
that right sided colonic growth are aggressive than left sided colorectal 
growth, Our study with being KRAS mutation higher on right side 
prompts us further insights of correlation between tumor aggressiveness 
with KRAS mutational status. 
Also a study by Loree JM et al.
(85)
with 1,876 patients of 
colorectal cancer compared mutation analysis according to 
location.They stressed the significance of  precise tumor location rather 
than classifying as right and left sided colonic carcinomas.Mutations 
prevalence differed by sides and locations for KRAS,TP 53, BRAF,PTEN 
,PIK4CA,SMAD4 within the right and left sided tumors.  
In a study byLiu et al.2011 
(84)
 with 217 cases of CRC with 
KRAS mutation testing, the distribution of  KRAS mutated cases were 
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observed as follows: 37% were right sided colon , 33% were left sided 
colon, 13% by rectal tumors and other sites of colon ( like hepatic/ 
splenic flexures) included 25%. There was no statistical significance 
between tumor site and KRAS mutation in this study which was alike 
our study. 
Table-8 -shows KRAS exprseeion in association with histological 
tumor gradings 
KRAS Mutated in Li  J et al 
(86)
 
Al-Allawi  
et al 
(56)
 
Current Study 
Well diff (Gr-I) 22.54% 25% 33.33% 
Moderately Diff (Gr-II) 52.62% 62.5% 66.67% 
Poorly diff (Gr-III) 24.84% 12.5% 0% 
CORRELATING THE EXPRESSION KRAS MUTATION 
WITH HISTOLOGICAL GRADING 
    Current study showed that most of KRAS mutated cases were of  
moderately differentiated grade(66.67%) followed by well differentiated 
type (33.33%).This is in par with studies by Li J et al. 2014
(84)
  and     
Al-allawi et al .
(56)
 However there is no significant correlation seen 
between  histological grade of  tumor and  KRAS mutational status.  
CORRELATING THE EXPRESSION OF KRAS WITH „T‟ 
STAGING 
      In current study KRAS mutation were seen in 80% of T4 cases, 
whereby depth of invasion of tumor is into serosa and periserosal 
 
107 
fat.Remaining 20% of T2 tumors were mutated. KRAS mutation shows 
predilection for tumors of T4 stage as per our study. 
Kim HS et al.2016 
(87)
 study picturised that among the KRAS 
mutant types,most of them were of T3 staging as against our study 
results.However,There is no statistical significance between „T‟ staging 
and KRAS mutational status.  
In Liu et al 
(84)
 study ,T3 staged tumors were most commonly 
associated with KRAS mutated cases .Both T3 and T4 stage tumors(T3 + 
T4=60%)  frequently show KRAS mutation as compared to T1(20%) and 
T2(0%) tumors.P value was 0.495 ,hence no statistical significance was 
obtained between these two. 
CORRELATING  EXPRESSION OF  KRAS  WITH 
ANGIOLYMPHATIC INVASION AND LYMPH NODAL STATUS 
It was observed that among the tumors which showed 
lymphovascular invasion,most of them were KRAS Wild type (90%) and 
p value was not statistically significant(p=0.787). Also most of cases 
with Nodal metastasis (9 out of 10 cases) were KRAS wild type .  
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Table-9: showing correlationof KRAS expression with angiolymphatic 
invasion 
Studies 
LV Invasion + Nodal Metastasis + 
KRAS + 
KRAS  
(wild) 
KRAS + KRAS (wild) 
Al-Allawi et al 
(56)
 54.2% 38.5% 50% 50% 
Niraj kumari et al 
(80)
 11.8% 18.6% 35.3% 52% 
Liu et al 
(84)
 27% 73% 32% 68% 
Current Study 10% 90% 20% 80% 
From above observations from Al-Allawi et al, Niraj kumara et al 
and Liu et al,it was inferred that both angiolymphatic invasion and nodal 
metastasis were less in mutated KRAS in comparison to wild-type 
KRAS .These were in concordance with our study results. This is of 
theranostically significant as most of nodal metastatic patients fall into 
KRAS wild type,hence they can be Sufficed with anti -EGFR therapy if 
needed at later stages.  
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Summary 
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SUMMARY 
This two years study on “Molecular expression of KRAS mutation 
in colorectal carcinoma and its correlation with clinicopathological 
findings” was done in Madras medical college and Rajiv Gandhi 
Government General hospital ,with sample size of 30 Formalin Fixed 
Paraffin Embedded (FFPE) blocks of biopsy proven colorectal 
carcinoma cases. 
 Out of these 30 cases,27 were of Conventional adenocarcinoma  
and 3 were mucinous carcinoma.  
 The mean age of presentation was 55.2 years and youngest age of 
presentation was 24 years. 
 Males constituted 56.7% and females accounted for 43.3% of 
cases ,with 
 Male : Female ratio of 1.3:1 .  
 The Commonest site of  tumour occurence was rectum followed 
by ascending  (Right sided) colon. 
 Majority of tumours showed ulceroprolifrative growth grossly and 
histologically glandular pattern was the commonest.  
 Half of the tumors were < 6cm and another 50% of tumors were >6cm 
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 Histologically most of the tumours (66.7%) were of moderately 
differentiated grade (Grade-II) 
 Individuals >50 years show predominantly moderately 
differentiated tumours and in <50 years both moderately and 
poorly differentiated grades seen.  
 Most of the cases (86.7%) belonged to “T4”stage  with invasion to 
serosa and periserosal pad of fat.  
 KRAS mutation detection by PCR and sanger sequencing yielded 
5 KRAS mutation positive cases(16.7%) and remaining 25 were 
KRAS Wild type. 
 There were also difficulties in standardization of DNA isolation 
and PCR cycling procedures as 5 of the samples initially showed 
poor DNA yield probably due to DNA fragmentation attributed to 
formalin over-soakage. 
 Among the 5 KRAS mutated cases, 2 of them were mucinous 
carcinoma, another 2 were moderately differentiated adenocarcinomas 
and one case was well differentiated type. 
 There was no significant correlation between expression of KRAS 
and histological grading of tumours.  
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 All 5 KRAS mutated cases were of age group >50 years. There is no 
statistical significance between KRAS expression and age of patient. 
 Majority of KRAS mutated cases resided in right sided(ascending 
colon) ,followed by rectum and no correlation was found between 
location of tumor and KRAS expression 
 Most KRAS mutated types were „T4 stage‟ . No significant 
correlation seen between T stage of tumor and KRAS expression 
 Tumours showing angiolymphatic invasion and nodal metastasis were 
less common in KRAS mutated type compared to KRAS wild type. 
 Thus the expression of  KRAS gene showed no significant 
correlation  with any of the clinicopathological parameters . 
 The absence of significant correlation of KRAS status with 
different variables are shared by most other literatures. 
However,though there is no signification correlation of  KRAS 
expression as such, some of our results were in concordance with other 
studies .Variables like older age of presentation, histologically tumours 
of moderately differentiated grade being the commonest , KRAS wild 
type cases exhibiting angiolymphatic and nodal metastasis higher than 
mutated types were all in par with most of  the literatures.  
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Limitations of the Study 
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LIMITATIONS OF THIS STUDY 
 Present study has relatively small sample size (n=30 cases).  
Hence, Larger clinical trials are required to confirm these 
findings. 
 Also the present study included only Codon 12 and Codon 13 of 
Exon 2 ,which is the commonest of KRAS mutations in colorectal 
carcinoma. However,analysis of these mutations alone are not 
sufficient to decide on Anti-EGFR therapy ,with several other 
mutational spots being present. 
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CONCLUSION 
Colorectal carcinoma ,though at one pole poses an impending threat 
of  increased estimated rates of incidences in future, boon of advanced 
molecular technologies and  regular screening methodologies at other pole 
prevents the human era falling into the trap of demise. This study evaluated 
the expression of KRAS gene in a hospital based setup, hence may not 
reflect its exact incidence in the community level. KRAS ,one of the 
significant genes involved in the multistep tumorigenesis of colorectal 
carcinoma ,plays an inevitable role in imparting aggressiveness to tumor 
flourishment and reduced apoptosis, thereby associated with poor survival 
.Mutations can occur in plenty number of exons and codons within it, hence 
many hidden novel mutations could throw a light to various targeted 
therapies,although codon 12 and 13 of exon 2 are the commonest. 
The utmost implication of knowing KRAS mutational status in 
colorectal carcinoma patients has been recently augmented by the fact that it 
is one of the important predictors of resistance to targeted therapy by 
Epidermal Growth Factor Receptor tyrosine kinase inhibitors like cetuximab 
and penitusumab (Anti-EGFR therapy). 
Thus these mutational studies aids the oncologists to decide on mode 
of treatment and assess the prognosis.Current study attempted to study the 
KRAS mutational status and to favour us, many of the patients were of 
KRAS wild type , paving a way for targeted therapy in case if at all needed.  
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ANNEXURE-I 
WHO CLASSIFICATION OF TUMORS OF COLON AND 
RECTUM 
EPITHELIAL TUMORS 
Premalignant Lesions 
 Adenoma 
-Tubular 
-Villous 
-Tubulovillous 
 Serrated lesions 
-Hyperplastic polyp 
-Traditional serrated adenoma 
-Sessile serrated adenoma/polyp 
 Hamartomas 
-Juvenile polyp 
-Peutz-Jeghers polyp 
-Cowden associated polyp 
Carcinomas 
o Adenocarcinoma 
-Mucinous carcinoma 
-Medullary carcinoma 
-Micropapillary carcinoma 
-Cribriform comedo type 
-Serrated adenocarcinoma 
-Signet ring cell carcinoma 
-Squamous cell carcinoma 
-Spindle cell carcinoma 
 
140 
-Basaloid (cloacogenic )carcinoma 
-Clear cell carcinoma 
-Hepatoid adenocarcinoma 
-Undifferentiated carcinoma 
o Neuroendocrine neoplasms 
-Neuroendocrine tumor(NET)    -- NET G1 Carcinoid /NET G2 
-Neuroendocrine carcinoma(NEC) –Large cell NEC/Small cell NEC 
o Mixed adeno neuroendocrine carcinoma 
o EC cell,Serotonin producing NET 
o L cell,glucagon like peptide producing,and PP/PPY producing NETs  
Mesenchymal Tumors 
 Lipoma 
 Leiomyoma 
 Hemangiomas 
 Angiosarcoma 
 Schwannoma 
 Gastrointestinal stromal tumor 
 Kaposi sarcoma 
 Leiomyosarcoma 
Lymphomas 
 Marginal zone B-cell Lymphoma (MALT)Type 
 Mantle cell lymphoma 
 Burkitt lymphoma 
 Diffuse large B-cell lymphoma 
Metastatic Tumors 
 
141 
ANNEXURE-II 
HISTOLOGICAL GRADING OF ADENOCARCINOMA 
Grading Differentiation Features 
Grade X Grade cannot be 
assessed 
 
Grade-I Well differentiated 
tumor 
Simple tubules,nuclear polarity 
easily discerned, Uniform sized 
nuclei 
Grade-II Moderately 
differentiated tumor 
Simple/complex/slightly-irregular 
tubules ,nuclear polarity lost 
Grade-III Poorly differentiated 
tumor 
Absence of glands,with Solid like 
pattern 
Grade-IV Undifferentiated tumor  
 
142 
ANNEXURE-III 
AJCC STAGING:
(52)
 
Primary Tumour(T) 
 TX-- Primary tumour cannot be assessed 
 T0-- No evidence of primary tumour 
 Tis-  Carcinoma in situ: intraepithelial or invasion of lamina propria 
 T1-- Tumour invades submucosa 
 T2-- Tumour invades muscularis propria  
 T3-- Tumour invades through muscularis propria into 
pericolorectal tissues 
 T4a- Tumour penetrates to the surface of  visceral peritoneum 
 T4b-Tumour directly invades or is adherent to other organs or 
structures. 
 
Regional Lymph Nodes(N) 
 Nx- Regional lymph nodes cannot be assessed 
 N0- No regional lymph node metastasis  
 N1- Metastasis in 1 to 3 regional lymph nodes 
 N2- Metastasis in 4 or more regional lymph nodes 
 
Distant Metastasis(M) 
 M0-No distant metastasis  
 M1-Distant metastasis 
 M1a-Metastasis confined to one organ or site 
 M1b-Metastasis in ≥1 organ/site 
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ANNEXURE -IV 
AJCC PATHOLOGIC STAGE GROUPS 
STAGE 0 Tis N0M0 
STAGE I T1N0M0 
T2N0M0 
STAGE II T3N0M0 
T4a/4b N0 M0 
STAGE III Any T N1M0 
Any T N2M0 
STAGE IV Any T Any N M1 
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S.No Bx.NO AGE SEX 
AGE 
RANGE 
SITE GROSS LESION SIZE HPE-PATTERN INFILTRATION TYPE GRADE INVASION LYMPHNODES STAGE 
KRAS 
MUTATION 
1 7170/18 60 F 51-60 RT.ASC.COLON 
ULCERO 
PROLIFERATIVE 
4.5X3.5X1CM SHEETS/NESTS/GLANDS SEROSA 
INFILTRATING 
ADENOCA. 
MOD LV -/PN- 
7NODES-
REACTIVE 
pT4aN0Mx DETECTED 
2 7174/18 65 F 61-70 RECTUM PEDUNCULATED POLYP 4X3.5X4CM VILLOGLANDULAR 
MUSCULARIS 
PROPRIA 
INFILTRATING 
ADENOCA. 
WELL LV-/PN- 
4NODES-
REACTIVE 
T2N0MX DETECTED 
3 4019/18 60 F 51-60 SIGMOID COLON ULCEROPROLIFERATIVE 8X4X2CM GLAND/PAPILLAE SEROSA 
INFILTRATING 
ADENOCA. 
MOD 
LV+/ 
PERINEURAL - 
1/3-METS T4aN1MX 
NOT 
DETECTED 
4 4287/18 80 F 71-80 RECTOSIGMOID ULCEROPROLIFERATIVE 6X3X1CM PAPILLAE/GLANDS SEROSA 
INFILTRATING 
ADENOCA. 
MOD 
LV+/PERINEURAL 
- 
2/8-METS T4aN1bMX 
NOT 
DETECTED 
5 4475/18 55 F 51-60 RT.ASC.COLON 
ULCEROPROLIFERATIVE 
WITH POLYP 
6X5X3CM GLAND/PAPILLAE SEROSA 
INFILTRATING 
ADENOCA. 
MOD LV-/PN- 
10 NODES-
REACTIVE 
T4aNXMX DETECTED 
6 4667/18 55 M 51-60 RT.ASC.COLON ULCERATED 7X3X3CM GLANDS SEROSA 
INFILTRATING 
ADENOCA. 
MOD LV-/PN- 
4NODES-
REACTIVE 
T4aNXMX 
NOT 
DETECTED 
7 4703/18 57 M 51-60 RT.ASC.COLON ULCEROPROLIFERATIVE 7X5X4CM PAPILLAE/GLANDS SEROSA 
INFILTRATING 
ADENOCA. 
MOD LV-/PN- 
11NODES-
REACTIVE 
T4aN0MX 
NOT 
DETECTED 
8 5182/18 65 M 61-70 RT.ASC.COLON PROLIFERATIVE 8X4X6CM GLANDULAR/PAPILLAE SEROSA 
INFILTRATING 
MUCINOUS 
ADENOCA. 
  LV-/PN- 
2NODES-
REACTIVE 
T4aNXMX 
NOT 
DETECTED 
9 7442/18 45 F 41-50 RECTUM INFILTRATING 4X3X3CM GLANDULAR SEROSA 
INFILTRATING 
ADENOCA. 
MOD LV-/PN- NO NODES T4aNxMX 
NOT 
DETECTED 
10 7476/18 50 M 41-50 RECTUM POLYPOIDAL 2X2X1.5CM POLYPOIDAL SUBMUCOSA 
INFILTRATING 
ADENOCA. 
WELL LV-/PN- 
12NODES-
REACTIVE 
T1NXMX 
NOT 
DETECTED 
11 7497/18 30 F 21-30 SIGMOID COLON INFILTRATING 3.5X2X0.5CM GLAND SEROSA 
INFILTRATING 
ADENOCA. 
MOD LV-/PN- 
12NODES-
REACTIVE 
T4aN0MX 
NOT 
DETECTED 
12 7657/18 60 F 51-60 RT.ASC.COLON ULCEROPROLIFERATIVE 6X4.5X3.5CM VILLOGLANDULAR SEROSA 
INFILTRATING 
ADENOCA. 
WELL 
LV+/PERINEURAL 
- 
3/23-METS T4aN1bMX 
NOT 
DETECTED 
13 7706/18 56 M 51-60 RT.ASC.COLON ULCERPROLIFERATIVE  10X6X6CM GLANDS 
PERISEROSAL 
PAD OF FAT 
MUCINOUS 
ADENOCA. 
  
LV+/PERINEURAL 
- 
1/14-METS T4aN1aMX  DETECTED 
14 7776/18 47 M 41-50 DESC.COLON ULCERPROLIFERATIVE  10X6.5X4CM SHEETS/NESTS SEROSA 
INFILTRATING 
ADENOCA. 
POORLY LV-/PN- NO NODES T4aNXMX 
NOT 
DETECTED 
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15 7856/18 67 M 61-70 RECTUM ULCEROPROLIFERATIVE 3X1.5CM CRIBRIFORM SEROSA 
INFILTRATING 
ADENOCA. 
MOD LV-/PN- 
2NODES-
REACTIVE 
T4aNXMX 
NOT 
DETECTED 
16 1306/18 26 M 21-30 RECTUM ULCERATED 4X4X2.5CM GLANDS SEROSA 
INFILTRATING 
ADENOCA. 
POORLY LV-/PN- NO NODES T4aNXMX 
NOT 
DETECTED 
17 1317/18 72 F 71-80 RECTUM ULCERATED 2.5X1.5CM GLANDS SEROSA 
INFILTRATING 
ADENOCA. 
MOD LV-/PN- NO NODES T4aNXMX 
NOT 
DETECTED 
18 1318/18 60 F 51-60 RT.ASC.COLON PROLIFERATIVE 3X2X2CM GLAND SEROSA 
INFILTRATING 
ADENOCA. 
MOD LV-/PN- 
4NODES-
REACTIVE 
T4aNxMX 
NOT 
DETECTED 
19 1453/18 56 F 51-60 RECTOSIGMOID NODULAR 3X2X2CM GLANDS SEROSA 
INFILTRATING 
ADENOCA. 
MOD LV-/PN- 
4NODES-
REACTIVE 
T4aNXMX 
NOT 
DETECTED 
20 1573/18 62 M 61-70 HEPATIC FLEXURE 
CIRCUMFERENTIAL 
INFILTRATIVE  GROWTH 
6X3X2CM GLAND,PAPILLARY SEROSA 
INFILTRATING 
ADENOCA. 
MOD 
LV+/PERINEURAL 
- 
1/12-METS T4aN1aMX 
NOT 
DETECTED 
21 2240/18 53 M 51-60 RECTUM ULCEROPROLIFERATIVE 4X2.5X5CM PAPILLAE/GLANDS 
MUSCULARIS 
PROPRIA 
INFILTRATING 
ADENOCA. 
MOD 
LV+/PERINEURAL 
- 
3/10 METS T2N1bMX 
NOT 
DETECTED 
22 1075/18 38 M 31-40 
SIGMOID 
COLON+BLADDER 
INFILTRATION 
ULCEROPROLI/ 
NODULARITY 
8X8X6CM GLANDS SEROSA 
INFILTRATING 
ADENOCA. 
MOD 
LV+/PERINEURAL 
- 
5NODES-
REACTIVE 
T4bNXMX 
NOT 
DETECTED 
23 1161/18 65 M 61-70 HEPATIC FLEXURE ULCEROPROLIFERATIVE 2.5X1CM GLANDS SEROSA 
INFILTRATING 
ADENOCA. 
MOD LV-/PN- 
5NODES-
REACTIVE 
T4aNXMX 
NOT 
DETECTED 
24 6964/18 65 F 61-70 RECTUM ULCEROPROLIFERATIVE 6X4X2CM IRREGULAR GLANDS SEROSA 
INFILTRATING 
ADENOCA. 
MOD 
LV+/PERINEURAL 
- 
1/2-METS T4aNXMX 
NOT 
DETECTED 
25 6774/18 24 M 21-30 SPLENIC FLEXURE ULCEROPROLIFERATIVE 16.5X7.5X2.5CM SOLID SHEETS,SIGNETRING SEROSA 
INFILTRATING 
ADENOCA. 
POORLY 
LV+/PERINEURAL 
- 
1/12-METS T4aN1MX 
NOT 
DETECTED 
26 8877/17 60 F 51-60 
RECTUM WITH 
LIVER METS 
ULCEROPROLIFERATIVE 4X4X3CM GLANDULAR/PAPILLARY SEROSA+ 
INFILTRATING 
ADENOCA. 
MOD LV-/PN- 
6NODES-
REACTIVE 
T4aNXM1 
NOT 
DETECTED 
27 3159/17 66 M 61-70 
SIGMOID COLON 
WITH ILEAL 
INFILTRATION 
ULCEROPROLIFERATIVE 6.5X6CM GLANDS 
PERISEROSAL 
PAD OF FAT 
INFILTRATING 
ADENOCA. 
WELL LV-/PN- 
4NODES-
REACTIVE 
T4bNXMX 
NOT 
DETECTED 
28 6695/17 65 M 61-70 TRANSVERSE COLON ULCEROPROLIFERATIVE 3X3X1CM GLANDULAR 
PERISEROSAL 
PAD OF FAT 
INFILTRATING 
ADENOCA. 
WELL 
LV+/PERINEURAL 
- 
1/6-METS T4bNXMX 
NOT 
DETECTED 
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29 6589/17 65 M 61-70 
RECTUM+POSTERIOR 
BLADDER 
INFILTRATION 
INFILTRATING 10X7X3CM PAPILLAE/GLANDS,SIGNETRING SEROSA 
INFILTRATING 
MUCINOUS 
ADENOCA. 
  LV-/PN- 
6NODES-
REACTIVE 
T4bNXMX  DETECTED 
30 8275/17 27 M 21-30 RECTUM ULCEROPROLIFERATIVE 3X2X2CM SHEETS/NESTS,SIGNET RING 
MUSCULARIS 
PROPRIA 
INFILTRATING 
ADENOCA. 
POORLY LV+/PN + 6/10-METS T3N2aMx 
NOT 
DETECTED 
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